BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811. [PMID: 15940615 DOI: 10.1053/j.gastro.2005.03.003] [Cited by in Crossref: 734] [Cited by in F6Publishing: 651] [Article Influence: 43.2] [Reference Citation Analysis]
Number Citing Articles
1 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
2 Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol. 2012;27:487-492. [PMID: 22098019 DOI: 10.1111/j.1440-1746.2011.06958.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
3 Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR. Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. J Crohns Colitis 2018;12:289-97. [PMID: 29121178 DOI: 10.1093/ecco-jcc/jjx146] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
4 Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25:19-37. [PMID: 17229218 DOI: 10.1111/j.1365-2036.2006.03131.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 6.2] [Reference Citation Analysis]
5 Grimm MC. New and emerging therapies for inflammatory bowel diseases. Journal of Gastroenterology and Hepatology 2009;24:S69-74. [DOI: 10.1111/j.1440-1746.2009.06074.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
6 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zoccali M, Fichera A. Minimally invasive approaches for the treatment of inflammatory bowel disease. World J Gastroenterol 2012; 18(46): 6756-6763 [PMID: 23239913 DOI: 10.3748/wjg.v18.i46.6756] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
8 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
9 Kucharzik T, Dignaß A, Siegmund B. Aktualisierung der Colitis ulcerosa Leitlinie 2020. Z Gastroenterol 2020;58:1209-32. [DOI: 10.1055/a-1296-3494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Jain S, Ahuja V, Limdi JK. Optimal management of acute severe ulcerative colitis. Postgrad Med J. 2019;95:32-40. [PMID: 30636193 DOI: 10.1136/postgradmedj-2018-136072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
11 Chaudhary MA, Fan T. Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands. Biol Ther. 2013;3:45-60. [PMID: 24392304 DOI: 10.1007/s13554-012-0007-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
12 Tøttrup A, Erichsen R, Sværke C, Laurberg S, Srensen HT. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open 2012;2:e000823. [PMID: 22492386 DOI: 10.1136/bmjopen-2012-000823] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
13 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Rodríguez-Moranta F, Márquez L, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, LLaó J, Gisbert JP, Aguas M, Arias L, Rodríguez-Lago I, Muñoz C, Alcaide N, Calvet X, Rodríguez C, Montoro MA, García S, De Castro ML, Piqueras M, Pareja L, Ribes J, Panés J, Esteve M; ENEIDA registry of GETECCU. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry. Am J Gastroenterol 2018;113:1009-16. [PMID: 29713028 DOI: 10.1038/s41395-018-0057-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
14 Monteleone G, Pallone F, Caprioli F. Investigational cytokine-targeted therapies for ulcerative colitis. Expert Opin Investig Drugs 2013;22:1123-32. [PMID: 23802627 DOI: 10.1517/13543784.2013.813931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Gómez Senent S, Gomollón F, Calvet X, García-planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Pérez Nyssen O, Gisbert JP. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study: Infliximab after ciclosporin failure in ulcerative colitis. Alimentary Pharmacology & Therapeutics 2012;35:275-83. [DOI: 10.1111/j.1365-2036.2011.04934.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 7.5] [Reference Citation Analysis]
16 Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007;26:779-794. [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
17 Guthery SL, Dong L, Dean MJ, Holubkov R. US estimates of hospitalized pediatric patients with ulcerative colitis: Implications for multicenter clinical studies: . Inflammatory Bowel Diseases 2008;14:1253-8. [DOI: 10.1002/ibd.20521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis 2013;28:287-93. [DOI: 10.1007/s00384-012-1602-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
19 Irving PM, Gibson PR. Infliximab: Getting the most for your money. J Gastroenterol Hepatol 2007;22:1559-61. [DOI: 10.1111/j.1440-1746.2007.05003.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Nakamura T, Nagahori M, Kanai T, Watanabe M. Current Pharmacologic Therapies and Emerging Alternatives in the Treatment of Ulcerative Colitis. Digestion 2008;77:36-41. [DOI: 10.1159/000111486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Daperno M, Sostegni R, Pera A, Rognone D, Rigazio C, Ercole E, Crocellà L, Lavagna A, Rocca R. The role of endoscopic assessment in ulcerative colitis in the era of infliximab. Digestive and Liver Disease 2008;40:S220-4. [DOI: 10.1016/s1590-8658(08)60529-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Molnár T, Farkas K, Szepes Z, Nagy F, Wittmann T. Infliximab rescue therapy in steroid-refractory ulcerative colitis: is more really more?: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2011;33:412-3. [DOI: 10.1111/j.1365-2036.2010.04529.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Andrew RE, Lauria A, Puleo FJ, Berg A, Stewart DB Sr. Inpatient infliximab is ineffective at preventing colectomy for steroid refractory extensive colitis. J Surg Res 2017;219:18-24. [PMID: 29078879 DOI: 10.1016/j.jss.2017.05.077] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Reindl W, Schmid RM, Huber W. Cyclosporin A treatment of steroid-refractory ulcerative colitis during pregnancy: report of two cases. Gut. 2007;56:1019. [PMID: 17566033 DOI: 10.1136/gut.2006.105288] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
25 Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Curr Gastroenterol Rep 2015;17:29. [PMID: 26143627 DOI: 10.1007/s11894-015-0454-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
26 Khalif IL, Nanaeva BA, Golovenko AO, Golovenko OV. [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. Ter Arkh 2015;87:34-8. [PMID: 25864346 DOI: 10.17116/terarkh201587234-38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
28 Grevenitis P, Thomas A, Lodhia N. Medical Therapy for Inflammatory Bowel Disease. Surgical Clinics of North America 2015;95:1159-82. [DOI: 10.1016/j.suc.2015.08.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
29 Acosta BM, García-bosch O, Souto R, Mañosa M, Miranda J, García-sanchez V, Gordillo J, Chacon S, Loras C, Carpio D, Maroto N, Menchén L, Rojas-feria M, Sierra M, Villoria A, Marin-jimenez I. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study: . Inflammatory Bowel Diseases 2012;18:812-7. [DOI: 10.1002/ibd.21821] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
30 Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020;115:202-210. [PMID: 31922959 DOI: 10.14309/ajg.0000000000000497] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
31 Selin KA, Hedin CRH, Villablanca EJ. Immunological networks defining the heterogeneity of inflammatory bowel diseases. J Crohns Colitis 2021:jjab085. [PMID: 33959743 DOI: 10.1093/ecco-jcc/jjab085] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 McClements D, Probert C. Managing acute severe ulcerative colitis in the hosptialised setting. Frontline Gastroenterol 2015;6:241-5. [PMID: 28839817 DOI: 10.1136/flgastro-2014-100459] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Song EM, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 33783045 DOI: 10.1111/jgh.15508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Risto A, Abdalla M, Myrelid P. Staging Pouch Surgery in Ulcerative Colitis in the Biological Era. Clin Colon Rectal Surg 2022;35:058-65. [DOI: 10.1055/s-0041-1740039] [Reference Citation Analysis]
35 Connelly TM, Devane L, Kelly JC, Wrafter P, Messaris E. The 100 classic papers in ulcerative colitis: a bibliometric analysis. Expert Rev Gastroenterol Hepatol 2016;10:1187-95. [PMID: 27531253 DOI: 10.1080/17474124.2016.1216786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
36 Navaneethan U, Shen B. Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg 2010;23:227-38. [PMID: 22131893 DOI: 10.1055/s-0030-1268249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
37 Andrew RE, Messaris E. Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new? World J Gastrointest Surg 2016; 8(9): 598-605 [PMID: 27721922 DOI: 10.4240/wjgs.v8.i9.598] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
38 Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:45-52. [PMID: 26395534 DOI: 10.1586/17474124.2015.1091308] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
39 Fleshner P, Melmed GY. Acute Severe Colitis: The Need for Joint Management between Gastroenterologists and Surgeons. Clin Colon Rectal Surg 2022;35:066-71. [DOI: 10.1055/s-0041-1740030] [Reference Citation Analysis]
40 Du L, Kim JJ, Shen J, Dai N. Crosstalk between Inflammation and ROCK/MLCK Signaling Pathways in Gastrointestinal Disorders with Intestinal Hyperpermeability. Gastroenterol Res Pract 2016;2016:7374197. [PMID: 27746814 DOI: 10.1155/2016/7374197] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
41 Jørandli JW, Thorsvik S, Skovdahl HK, Kornfeld B, Sæterstad S, Gustafsson BI, Sandvik AK, van Beelen Granlund A. The serotonin reuptake transporter is reduced in the epithelium of active Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2020;319:G761-8. [PMID: 32967429 DOI: 10.1152/ajpgi.00244.2020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
42 Kaur M, Targan SR. Ulcerative colitis: steroid-refractory ulcerative colitis-ciclosporin or infliximab? Nat Rev Gastroenterol Hepatol 2013;10:8-9. [PMID: 23229328 DOI: 10.1038/nrgastro.2012.235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
43 Bélard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, Thomsen H, Brylov A, Hetland ML, Nordgaard-lassen I, Ravn P. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection: . Inflammatory Bowel Diseases 2011;17:2340-9. [DOI: 10.1002/ibd.21605] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 7.8] [Reference Citation Analysis]
44 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
45 Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 64-77 [PMID: 24415859 DOI: 10.3748/wjg.v20.i1.64] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 84] [Article Influence: 11.3] [Reference Citation Analysis]
46 Jijon HB, Buret A, Hirota CL, Hollenberg MD, Beck PL. The EGF receptor and HER2 participate in TNF-α-dependent MAPK activation and IL-8 secretion in intestinal epithelial cells. Mediators Inflamm 2012;2012:207398. [PMID: 22988345 DOI: 10.1155/2012/207398] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
47 Kaplan GG, Lim A, Seow CH, Moran GW, Ghosh S, Leung Y, Debruyn J, Nguyen GC, Hubbard J, Panaccione R. Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World J Gastroenterol 2015; 21(4): 1251-1260 [PMID: 25632199 DOI: 10.3748/wjg.v21.i4.1251] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
48 Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol. 2010;25:886-891. [PMID: 20546441 DOI: 10.1111/j.1440-1746.2009.06206.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
49 Rizzo G, Armuzzi A, Pugliese D, Verbo A, Papa A, Mattana C, Rapaccini GL, Guidi L, Coco C. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis. 2011;26:1435-1444. [PMID: 21594668 DOI: 10.1007/s00384-011-1236-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
50 Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010;105:1430-1436. [PMID: 20104217 DOI: 10.1038/ajg.2009.759] [Cited by in Crossref: 88] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
51 Myrelid P, Salim SY, Darby T, Almer S, Melgar S, Andersson P, Söderholm JD. Effects of anti-inflammatory therapy on bursting pressure of colonic anastomosis in murine dextran sulfate sodium induced colitis. Scand J Gastroenterol 2015;50:991-1001. [PMID: 25861827 DOI: 10.3109/00365521.2014.964760] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
52 Ollech JE, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer PH, Christensen B, Pekow J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;51:637-43. [DOI: 10.1111/apt.15616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
53 Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;CD008794. [PMID: 21328309 DOI: 10.1002/14651858.cd008794.pub2] [Cited by in Crossref: 189] [Cited by in F6Publishing: 200] [Article Influence: 17.2] [Reference Citation Analysis]
54 Fichera A, Silvestri MT, Hurst RD, Rubin MA, Michelassi F. Laparoscopic restorative proctocolectomy with ileal pouch anal anastomosis: a comparative observational study on long-term functional results. J Gastrointest Surg. 2009;13:526-532. [PMID: 19015927 DOI: 10.1007/s11605-00] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM; BASBUC INVESTIGATORS. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther. 2006;23:1435-1442. [PMID: 16669958 DOI: 10.1111/j.1365-2036.2006.02904.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
56 Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45:801-813. [PMID: 28112419 DOI: 10.1111/apt.13948] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
57 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
58 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
59 Nalagatla N, Falloon K, Tran G, Borren NZ, Avalos D, Luther J, Colizzo F, Garber J, Khalili H, Melia J, Bohm M, Ananthakrishnan AN. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:502-509.e1. [PMID: 29944926 DOI: 10.1016/j.cgh.2018.06.031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
60 Spiegel BM, Ho W, Esrailian E, Targan S, Higgins PD, Siegel CA, Dubinsky M, Melmed GY. Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol. 2009;7:168-174, 174.e1. [PMID: 18952199 DOI: 10.1016/j.cgh.2008.08.029] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
61 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909-1915. [PMID: 23063316 DOI: 10.1016/s0140-6736(12)61084-8] [Cited by in Crossref: 342] [Cited by in F6Publishing: 124] [Article Influence: 34.2] [Reference Citation Analysis]
62 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
63 Scholmerich J. Inflammatory Bowel Disease: Pandora's Box, Present and Future. Annals of the New York Academy of Sciences 2006;1072:365-78. [DOI: 10.1196/annals.1326.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
64 Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. [PMID: 17129815 DOI: 10.1016/j.gtc.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
65 Halaweish I, Alam HB. Surgical Management of Severe Colitis in the Intensive Care Unit. J Intensive Care Med 2015;30:451-61. [DOI: 10.1177/0885066614534941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
66 Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-S25; quiz S26. [PMID: 21472012 DOI: 10.1038/ajg.2011.58] [Cited by in Crossref: 177] [Cited by in F6Publishing: 165] [Article Influence: 16.1] [Reference Citation Analysis]
67 Vexler V, Woo J. Antibody treatment of ulcerative colitis. Drug Discovery Today: Therapeutic Strategies 2006;3:353-60. [DOI: 10.1016/j.ddstr.2006.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. Simple score to identify colectomy risk in ulcerative colitis hospitalizations. Inflamm Bowel Dis. 2010;16:1532-1540. [PMID: 20091926 DOI: 10.1002/ibd.21225] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
69 Miheller P, Kiss LS, Lorinczy K, Lakatos PL. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opinion on Biological Therapy 2012;12:179-92. [DOI: 10.1517/14712598.2012.644271] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
70 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
71 Croker BA, Rickard JA, Shlomovitz I, Al-obeidi A, D'cruz AA, Gerlic M. Necroptosis. In: Radosevich J, editor. Apoptosis and Beyond. Hoboken: John Wiley & Sons, Inc.; 2018. pp. 99-128. [DOI: 10.1002/9781119432463.ch6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Dan-nielsen S, Wewer V, Paerregaard A, Hansen LF, Nielsen RG, Lange A, Jakobsen C. Does Infliximab Prevent Colectomy in Acute and Chronic Active Ulcerative Colitis? Journal of Pediatric Gastroenterology & Nutrition 2014;58:768-72. [DOI: 10.1097/mpg.0000000000000340] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Chitul A, Voiosu AM, Marinescu M, Caraiola S, Nicolau A, Badea GC, Pârvu MI, Ionescu RA, Mateescu BR, Voiosu MR, Băicuş CR, Rimbaş M. Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis. Rom J Intern Med 2017;55:44-52. [PMID: 28103201 DOI: 10.1515/rjim-2017-0001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
75 Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis 2018;24:1291-7. [PMID: 29506124 DOI: 10.1093/ibd/izx105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
76 Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Review of Clinical Immunology 2014;9:77-92. [DOI: 10.1586/eci.12.91] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
77 Ford AC, Peyrin-biroulet L. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology 2013;108:1268-76. [DOI: 10.1038/ajg.2013.138] [Cited by in Crossref: 226] [Cited by in F6Publishing: 194] [Article Influence: 25.1] [Reference Citation Analysis]
78 Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Viscido A, Annese V, Riegler G, Meucci G. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007;26:747-756. [PMID: 17697208 DOI: 10.1111/j.1365-2036.2007.03415.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 7.7] [Reference Citation Analysis]
79 Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno MN. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015;6:65-77. [PMID: 25729557 DOI: 10.1177/2040622314563929] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
80 Moosvi Z, Duong J, Bechtold ML, Nguyen DL. Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2021;33:799-816. [PMID: 33079779 DOI: 10.1097/MEG.0000000000001944] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Hassan C, Zullo A, Ierardi E, Burattini O, De Francesco V, Morini S. Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula. Gut 2006;55:589-90. [PMID: 16531548 DOI: 10.1136/gut.2005.084756] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
82 D’Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn’s disease. Curr Gastroenterol Rep. 2006;8:506-512. [PMID: 17105690 DOI: 10.1007/s11894-006-0041-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
83 Garud S, Brown A, Cheifetz A, Levitan EB, Kelly CP. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci 2008;53:875-91. [PMID: 17934839 DOI: 10.1007/s10620-007-9954-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
84 Liu S, Eisenstein S. State-of-the-art surgery for ulcerative colitis. Langenbecks Arch Surg 2021;406:1751-61. [PMID: 34453611 DOI: 10.1007/s00423-021-02295-6] [Reference Citation Analysis]
85 Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319-330. [PMID: 16842459 DOI: 10.1111/j.1365-2036.2006.02974.x] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 8.9] [Reference Citation Analysis]
86 Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, O'Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM; Australian Inflammatory Bowel Disease Association (AIBDA). Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients. Intern Med J 2015;45:659-66. [PMID: 25732268 DOI: 10.1111/imj.12732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
87 Steenholdt C, Al-Khalaf M, Ainsworth MA, Brynskov J. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis. 2012;6:358-361. [PMID: 22405174 DOI: 10.1016/j.crohns.2011.10.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
88 Van Assche G, Vermeire S, Rutgeerts P. Immunosuppression in inflammatory bowel disease: traditional, biological or both?: . Current Opinion in Gastroenterology 2009;25:323-8. [DOI: 10.1097/mog.0b013e32832c073a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
89 Wang X, Wong K, Ouyang W, Rutz S. Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. Cold Spring Harb Perspect Biol 2019;11:a028548. [PMID: 29038121 DOI: 10.1101/cshperspect.a028548] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 14.3] [Reference Citation Analysis]
90 Perera S, Yang S, Stott-Miller M, Brady J. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. J Health Econ Outcomes Res 2018;6:96-112. [PMID: 32685575 DOI: 10.36469/9791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A. Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol 2011;4:9-17. [PMID: 21694867 DOI: 10.2147/CEG.S16168] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
92 Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract. 2012;2012:642923. [PMID: 22474447 DOI: 10.1155/2012/642923] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
93 Bregnbak D, Mortensen C, Bendtsen F. Infliximab and complications after colectomy in patients with ulcerative colitis. J Crohns Colitis. 2012;6:281-286. [PMID: 22405163 DOI: 10.1016/j.crohns.2011.08.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
94 Allison J, Herrinton LJ, Liu L, Yu J, Lowder J. Natural History of Severe Ulcerative Colitis in a Community-Based Health Plan. Clinical Gastroenterology and Hepatology 2008;6:999-1003. [DOI: 10.1016/j.cgh.2008.05.022] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
95 Wang F, Schwarz BT, Graham WV, Wang Y, Su L, Clayburgh DR, Abraham C, Turner JR. IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology. 2006;131:1153-1163. [PMID: 17030185 DOI: 10.1053/j.gastro.2006.08.022] [Cited by in Crossref: 206] [Cited by in F6Publishing: 195] [Article Influence: 12.9] [Reference Citation Analysis]
96 Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
97 Magnusson MK, Strid H, Isaksson S, Bajor A, Lasson A, Ung K, Öhman L. Cultured blood T-cell responses predict anti-TNF therapy response in patients with ulcerative colitis. Aliment Pharmacol Ther 2015;41:1149-61. [DOI: 10.1111/apt.13192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
98 Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-7. [PMID: 17327942 DOI: 10.1080/00365520600979369] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
99 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Berinstein JA, Sheehan JL, Dias M, Berinstein EM, Steiner CA, Johnson LA, Regal RE, Allen JI, Cushing KC, Stidham RW, Bishu S, Kinnucan JAR, Cohen-Mekelburg SA, Waljee AK, Higgins PDR. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00576-0. [PMID: 34048936 DOI: 10.1016/j.cgh.2021.05.038] [Reference Citation Analysis]
101 D'Haens G. Infliximab for ulcerative colitis: finally some answers. Gastroenterology 2005;128:2161-4. [PMID: 15940648 DOI: 10.1053/j.gastro.2005.04.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
102 Ogino T, Mizushima T, Matsuda C, Mori M, Doki Y. Essential updates 2018/2019: Colorectal (benign): Recent updates (2018-2019) in the surgical treatment of benign colorectal diseases. Ann Gastroenterol Surg 2020;4:30-8. [PMID: 32021956 DOI: 10.1002/ags3.12304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
103 Chu ZX, Chen HQ, Zhang M, Qin HL. Lactobacillus plantarum attenuates up-regulation of adhesion molecules expression in IL-10 gene knockout mice with colitis. Shijie Huaren Xiaohua Zazhi 2009; 17(12): 1190-1196 [DOI: 10.11569/wcjd.v17.i12.1190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Levy LC, Coburn ES, Choi S, Holubar SD. The management of the hospitalized ulcerative colitis patient: the medical-surgical conundrum. Current Opinion in Gastroenterology 2020;36:265-76. [DOI: 10.1097/mog.0000000000000637] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Fiorino G, Danese S, Giacobazzi G, Spinelli A. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. Digestive and Liver Disease 2021;53:403-8. [DOI: 10.1016/j.dld.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
106 Huang X, Lv B, Jin H, Zhang S. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis. Eur J Clin Pharmacol 2011;67:759-66. [DOI: 10.1007/s00228-011-1079-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
107 Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:219-29. [DOI: 10.1586/egh.09.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
108 Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:447-58. [PMID: 24444171 DOI: 10.1111/apt.12624] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 13.1] [Reference Citation Analysis]
109 Shen B. Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: The price we have to pay?: . Inflammatory Bowel Diseases 2008;14:1019-21. [DOI: 10.1002/ibd.20407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
110 Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255-1262. [PMID: 16484504 DOI: 10.1136/gut.2005.081794] [Cited by in Crossref: 290] [Cited by in F6Publishing: 233] [Article Influence: 18.1] [Reference Citation Analysis]
111 Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482-513. [PMID: 26725569 DOI: 10.1111/apt.13491] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
112 Sjöberg M, Walch A, Meshkat M, Gustavsson A, Järnerot G, Vogelsang H, Hertervig E, Novacek G, Friis-Liby I, Blomquist L. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18:212-218. [PMID: 21438096 DOI: 10.1002/ibd.21680] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
113 Arai Y, Arihiro S, Matsuura T, Kato T, Matsuoka M, Saruta M, Mitsunaga M, Matsuura M, Fujiwara M, Okayasu I, Ito S, Tajiri H. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. Inflamm Bowel Dis. 2014;20:1208-1216. [PMID: 24846719 DOI: 10.1097/mib.0000000000000062] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
114 Marini JC, Sendecki J, Cornillie F, Popp JW Jr, Black S, Blank M, Gils A, Van Stappen T, Hamann D, Rispens T, Thérien L, Chun K, Shankar G. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®. AAPS J 2017;19:161-71. [PMID: 27600137 DOI: 10.1208/s12248-016-9981-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
115 Bojic D, Radojicic Z, Nedeljkovic-Protic M, Al-Ali M, Jewell DP, Travis SP. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. Inflamm Bowel Dis. 2009;15:823-828. [PMID: 19145641 DOI: 10.1002/ibd.20843] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
116 Zhao X, Lv C, Chen S, Zhi F. A role for the non-receptor tyrosine kinase ACK1 in TNF-alpha-mediated apoptosis and proliferation in human intestinal epithelial caco-2 cells. Cell Biol Int 2018;42:1097-105. [PMID: 28921811 DOI: 10.1002/cbin.10875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
117 Huang EH, Wicha MS. Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med. 2008;14:503-509. [PMID: 18929507 DOI: 10.1016/j.molmed.2008.09.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
118 Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN. CT-Visualized Colonic Mural Stratification Independently Predicts the Need for Medical or Surgical Rescue Therapy in Hospitalized Ulcerative Colitis Patients. Dig Dis Sci 2019;64:2265-72. [PMID: 30796684 DOI: 10.1007/s10620-019-05520-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
119 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 297] [Article Influence: 120.3] [Reference Citation Analysis]
120 Macdermott RP, Green JA, Ashley CC. What is the optimal therapy for severe ulcerative colitis?: . Inflammatory Bowel Diseases 2008;14:S228-31. [DOI: 10.1002/ibd.20514] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
121 Gibson DJ, Doherty J, McNally M, Campion J, Keegan D, Keogh A, Kennedy U, Byrne K, Egan LJ, McKiernan S, MacCarthy F, Sengupta S, Sheridan J, Mulcahy HE, Cullen G, Slattery E, Kevans D, Doherty GA. Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterol 2020;11:441-7. [PMID: 33104766 DOI: 10.1136/flgastro-2019-101335] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Wang Y, Makadia R, Knoll C, Hardin J, Voss EA, Fife D, Davis K, Sloan S. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterol 2021;21:121. [PMID: 33731009 DOI: 10.1186/s12876-021-01708-6] [Reference Citation Analysis]
123 van Assche G, Vermeire S, Rutgeerts P. Emerging Biological Treatments in Inflammatory Bowel Diseases. Dig Dis 2006;24:131-6. [DOI: 10.1159/000090316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
124 Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, Chen M, Hu PJ, Andoh A, Kim HJ, Yang SK, Watanabe M, Ng SC, Hibi T, Hilmi IN, Suzuki Y, Han DS, Leung WK, Sollano J, Ooi CJ, Qian J. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol 2021;36:637-45. [PMID: 32672839 DOI: 10.1111/jgh.15185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther. 2012;36:922-928. [PMID: 23002804 DOI: 10.1111/apt.12060] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 7.2] [Reference Citation Analysis]
126 Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten A, Billiet T, Baert F, Wolthuis A, Van Assche G, Noman M, Hoffman I. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:531-538. [PMID: 25117777 DOI: 10.1016/j.cgh.2014.07.055] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 12.4] [Reference Citation Analysis]
127 Eshuis EJ, Al Saady RL, Stokkers PC, Ponsioen CY, Tanis PJ, Bemelman WA. Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. Journal of Crohn's and Colitis 2013;7:142-9. [DOI: 10.1016/j.crohns.2012.03.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
128 Cottone M, Scimeca D, Mocciaro F, Civitavecchia G, Perricone G, Orlando A. Clinical course of ulcerative colitis. Dig Liver Dis. 2008;40 Suppl 2:S247-S252. [PMID: 18598996 DOI: 10.1016/s1590-8658(08)60533-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
129 Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
130 Burger DC, Travis S. Colon salvage therapy for acute severe colitis: cyclosporine or infliximab?: . Current Opinion in Gastroenterology 2011;27:358-62. [DOI: 10.1097/mog.0b013e32834586e3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
131 Lees CW, Shand AG, Penman ID, Satsangi J, Arnott ID. Role of infliximab in ulcerative colitis: Further questions: . Inflammatory Bowel Diseases 2006;12:335-7. [DOI: 10.1097/01.mib.0000215095.69869.67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
132 Magnusson MK, Strid H, Sapnara M, Lasson A, Bajor A, Ung K, Öhman L. Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. ECCOJC 2016;10:943-52. [DOI: 10.1093/ecco-jcc/jjw051] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 12.0] [Reference Citation Analysis]
133 Sjöberg M, Magnuson A, Björk J, Benoni C, Almer S, Friis-Liby I, Hertervig E, Olsson M, Karlén P, Eriksson A. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther. 2013;38:377-387. [PMID: 23799948 DOI: 10.1111/apt.12387] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
134 Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, Reinisch W. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111:477-491. [PMID: 26856754 DOI: 10.1038/ajg.2016.7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 15.0] [Reference Citation Analysis]
135 Koutroubakis IE. Recent advances in the management of distal ulcerative colitis. World J Gastrointest Pharmacol Ther 2010; 1(2): 43-50 [PMID: 21577295 DOI: 10.4292/wjgpt.v1.i2.43] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
136 Nguyen GC, Prather CM. Is Keeping the Colon the Ultimate Marker of Success in Ulcerative Colitis? Gastroenterology 2009;137:1204-6. [DOI: 10.1053/j.gastro.2009.08.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
137 Kohn A. Is there a role for infliximab in severe ulcerative colitis?: The European experience: . Inflammatory Bowel Diseases 2008;14:S234-5. [DOI: 10.1002/ibd.20665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:78-91. [DOI: 10.1038/ncpgasthep0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
139 Baudet A, Colombel J, Cortot A, Dupas J, Brazier F, Savoye G, Lerebours E, Justum A, Reimund J. A fulminant colitis index greater or equal to 8 is not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks. Gastroentérologie Clinique et Biologique 2010;34:612-7. [DOI: 10.1016/j.gcb.2010.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
140 Bordeianou L, Maguire L. State-of-the-Art Surgical Approaches to the Treatment of Medically Refractory Ulcerative Colitis. J Gastrointest Surg 2013;17:2013-9. [DOI: 10.1007/s11605-013-2312-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
141 Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: Pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2010;31:486-492. [PMID: 19925496 DOI: 10.1111/j.1365-2036.2009.04204.x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 86] [Article Influence: 8.0] [Reference Citation Analysis]
142 Ho GT, Mowat A, Potts L, Cahill A, Mowat C, Lees CW, Hare NC, Wilson JA, Boulton-jones R, Priest M, Watts DA, Shand AG, Arnott ID, Russell RK, Wilson DC, Morris AJ, Satsangi J. Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008). Alimentary Pharmacology & Therapeutics 2009;29:527-34. [DOI: 10.1111/j.1365-2036.2008.03919.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
143 Régent A, Mouthon L. [Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases]. Presse Med 2009;38:761-73. [PMID: 19349142 DOI: 10.1016/j.lpm.2009.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
144 Fornaro R, Caratto M, Barbruni G, Fornaro F, Salerno A, Giovinazzo D, Sticchi C, Caratto E. Surgical and medical treatment in patients with acute severe ulcerative colitis. J Dig Dis. 2015;16:558-567. [PMID: 26315728 DOI: 10.1111/1751-2980.12278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
145 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
146 Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz 660. [PMID: 21407183 DOI: 10.1038/ajg.2011.73] [Cited by in Crossref: 374] [Cited by in F6Publishing: 353] [Article Influence: 34.0] [Reference Citation Analysis]
147 Annunziata ML, Hanauer SB. Calcineurin inhibition in severe ulcerative colitis: Lost in translation?: . Inflammatory Bowel Diseases 2012;18:809-11. [DOI: 10.1002/ibd.21848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
148 Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. Aliment Pharmacol Ther. 2013;37:855-866. [PMID: 23489068 DOI: 10.1111/apt.12284] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 7.7] [Reference Citation Analysis]
149 Lightner AL, Vogel JD, Carmichael JC, Keller DS, Shah SA, Mahadevan U, Kane SV, Paquette IM, Steele SR, Feingold DL. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. Dis Colon Rectum. 2020;63:1028-1052. [PMID: 32692069 DOI: 10.1097/dcr.0000000000001716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
150 Esteve M, Gisbert JP. Severe ulcerative colitis: At what point should we define resistance to steroids? World J Gastroenterol 2008; 14(36): 5504-5507 [PMID: 18810766 DOI: 10.3748/wjg.14.5504] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
151 Bernstein CN, Kornbluth A. Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis. Am J Gastroenterol 2017;112:1719-21. [PMID: 29109492 DOI: 10.1038/ajg.2017.282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
152 Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott ID. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther. 2013;38:935-945. [PMID: 24004000 DOI: 10.1111/apt.12473] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
153 Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007;102:2058-2069. [PMID: 17561966 DOI: 10.1111/j.1572-0241.2007.01343.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 152] [Article Influence: 9.8] [Reference Citation Analysis]
154 Yang J, Wu SJ, Dai WT, Li YX, Li YY. The human disease network in terms of dysfunctional regulatory mechanisms. Biol Direct 2015;10:60. [PMID: 26450611 DOI: 10.1186/s13062-015-0088-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
155 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
156 Ma R, Meng R, Zhang X, Sun Z, Lei Y. Correlation between fecal calprotectin, ulcerative colitis endoscopic index of severity and clinical outcome in patients with acute severe colitis. Exp Ther Med 2020;20:1498-504. [PMID: 32765673 DOI: 10.3892/etm.2020.8861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
157 Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R; Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194; author reply 195. [PMID: 22108451 DOI: 10.1038/ajg.2011.386] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 9.6] [Reference Citation Analysis]
158 Truong A, Zaghiyan KN, Mirocha J, Melmed GY, McGovern DPB, Syal G, Ha CY, Targan SR, Fleshner PR. Antitumour necrosis factor therapy is associated with de novo Crohn's disease after ileal pouch-anal anastomosis. Colorectal Dis 2021;23:2416-24. [PMID: 34157179 DOI: 10.1111/codi.15772] [Reference Citation Analysis]
159 Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, Bak Andersen I, Wewer V, Nørregaard P, Moesgaard F. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274-1282. [PMID: 16771949 DOI: 10.1111/j.1572-0241.2006.00552.x] [Cited by in Crossref: 360] [Cited by in F6Publishing: 349] [Article Influence: 22.5] [Reference Citation Analysis]
160 Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979-994. [PMID: 17012969 DOI: 10.1097/01.mib.0000231495.92013.5e] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
161 Naganuma M, Ichikawa H, Inoue N, Kobayashi T, Okamoto S, Hisamatsu T, Kanai T, Ogata H, Iwao Y, Hibi T. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 2010;45:936-43. [DOI: 10.1007/s00535-010-0244-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
162 Selvaggi F, Pellino G, Canonico S, Sciaudone G. Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:79-92. [PMID: 25517596 DOI: 10.1097/MIB.0000000000000232] [Cited by in Crossref: 56] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
163 Angelison L, Almer S, Eriksson A, Karling P, Fagerberg U, Halfvarson J, Thörn M, Björk J, Hindorf U, Löfberg R, Bajor A, Hjortswang H, Hammarlund P, Grip O, Torp J, Marsal J, Hertervig E; Swedish Organization for the Study of Inflammatory Bowel diseases (SOIBD). Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients. Aliment Pharmacol Ther 2017;45:519-32. [PMID: 28025840 DOI: 10.1111/apt.13893] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
164 Malik TA. Inflammatory Bowel Disease: Historical Perspective, Epidemiology, and Risk Factors. Surg Clin North Am. 2015;95:1105-1122, v. [PMID: 26596917 DOI: 10.1016/j.suc.2015.07.006] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
165 Baudet A, Rahmi G, Bretagne AL, Gloro R, Justum AM, Reimund JM. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother. 2008;9:447-457. [PMID: 18220494 DOI: 10.1517/14656566.9.3.447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
166 Tiu SPT, Hajirawala LN, Leonardi C, Davis KG, Orangio GR, Barton JS. Delayed Surgery Does Not Increase Risk in Urgent Colectomy for Ulcerative Colitis. Am Surg 2021;87:880-4. [PMID: 33280393 DOI: 10.1177/0003134820971576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Argollo MC, Kotze PG, Spinelli A, Gomes TN, Danese S. The impact of biologics in surgical outcomes in ulcerative colitis. Best Practice & Research Clinical Gastroenterology 2018;32-33:79-87. [DOI: 10.1016/j.bpg.2018.05.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
168 Rampton DS. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 2005;54:1360-2. [PMID: 16113045 DOI: 10.1136/gut.2005.076034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
169 Järnerot G. Infliximab or Cyclosporine for Severe Ulcerative Colitis. Gastroenterology 2006;130:286. [DOI: 10.1053/j.gastro.2005.11.037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
170 Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, Rutgeerts P. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760-765. [PMID: 16716758 DOI: 10.1016/j.cgh.2006.04.001] [Cited by in Crossref: 202] [Cited by in F6Publishing: 165] [Article Influence: 12.6] [Reference Citation Analysis]
171 Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
172 Aceituno M, García-Planella E, Heredia C, Zabana Y, Feu F, Domènech E, Gassull MA, Panés J. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008;14:347-52. [PMID: 18050296 DOI: 10.1002/ibd.20322] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
173 Laharie D, Rivière P. Letter: should we intensify infliximab in acute severe ulcerative colitis? Aliment Pharmacol Ther 2020;51:186-7. [DOI: 10.1111/apt.15520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
174 Reich KM, Chang HJ, Rezaie A, Wang H, Goodman KJ, Kaplan GG, Svenson LW, Lees G, Fedorak RN, Kroeker KI. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther. 2014;40:629-638. [PMID: 25039715 DOI: 10.1111/apt.12873] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 8.5] [Reference Citation Analysis]
175 Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, Proulx MC, Hubbard J, MacLean A, Buie D, Panaccione R. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107:1879-1887. [PMID: 23165448 DOI: 10.1038/ajg.2012.333] [Cited by in Crossref: 137] [Cited by in F6Publishing: 123] [Article Influence: 13.7] [Reference Citation Analysis]
176 Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, Daniel F, Beaugerie L, Cosnes J. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008;103:637-42. [PMID: 18047542 DOI: 10.1111/j.1572-0241.2007.01653.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
177 Katz J, Frank M. Prolonged fever after Infliximab infusion. World J Gastrointest Pharmacol Ther 2012; 3(3): 34-35 [PMID: 22966481 DOI: 10.4292/wjgpt.v3.i3.34] [Cited by in CrossRef: 2] [Article Influence: 0.2] [Reference Citation Analysis]
178 Biondi A, Zoccali M, Costa S, Troci A, Contessini-Avesani E, Fichera A. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol 2012; 18(16): 1861-1870 [PMID: 22563165 DOI: 10.3748/wjg.v18.i16.1861] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
179 Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64:1119-1128. [PMID: 30535888 DOI: 10.1007/s10620-018-5407-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
180 Ancowitz B, Shah SA. Infusion services in the gastroenterology practice. Gastrointest Endosc Clin N Am 2006;16:727-42. [PMID: 17098619 DOI: 10.1016/j.giec.2006.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
181 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
182 Yamaguchi T, Yoshida S, Tanaka S, Takemura Y, Oka S, Yoshihara M, Yamada H, Chayama K. Predicting the clinical response to cytapheresis in steroid-refractory or -dependent ulcerative colitis using contrast-enhanced ultrasonography. Scand J Gastroenterol 2009;44:831-7. [PMID: 19811342 DOI: 10.1080/00365520902839659] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
183 Katsanos KH, Maliouki M, Tatsioni A, Ignatiadou E, Christodoulou DK, Fatouros M, Tsianos EV. The role of colonoscopy in the management of intestinal obstruction: a 20-year retrospective study. BMC Gastroenterol 2010;10:130. [PMID: 21059218 DOI: 10.1186/1471-230X-10-130] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
184 Caprilli R, Clemente V, Frieri G. Historical evolution of the management of severe ulcerative colitis. Journal of Crohn's and Colitis 2008;2:263-8. [DOI: 10.1016/j.crohns.2008.03.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
185 Krane MK, Allaix ME, Zoccali M, Umanskiy K, Rubin MA, Villa A, Hurst RD, Fichera A. Preoperative Infliximab Therapy Does Not Increase Morbidity and Mortality After Laparoscopic Resection for Inflammatory Bowel Disease. Diseases of the Colon & Rectum 2013;56:449-57. [DOI: 10.1097/dcr.0b013e3182759029] [Cited by in Crossref: 47] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
186 Hara DB, Leite DF, Fernandes ES, Passos GF, Guimarães AO, Pesquero JB, Campos MM, Calixto JB. The relevance of kinin B1 receptor upregulation in a mouse model of colitis. Br J Pharmacol 2008;154:1276-86. [PMID: 18536758 DOI: 10.1038/bjp.2008.212] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
187 Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011;17:440-9. [PMID: 20645317 DOI: 10.1002/ibd.21383] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
188 Hart AL, Ng SC. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment Pharmacol Ther 2010;32:615-27. [PMID: 20626381 DOI: 10.1111/j.1365-2036.2010.04392.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
189 Lin YP, Thibodeaux CH, Peña JA, Ferry GD, Versalovic J. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis. 2008;14:1068-1083. [PMID: 18425802 DOI: 10.1002/ibd.20448] [Cited by in Crossref: 148] [Cited by in F6Publishing: 144] [Article Influence: 10.6] [Reference Citation Analysis]
190 Aratari A, Papi C, Clemente V, Moretti A, Luchetti R, Koch M, Capurso L, Caprilli R. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821-826. [PMID: 18472316 DOI: 10.1016/j.dld.2008.03.014] [Cited by in Crossref: 115] [Cited by in F6Publishing: 105] [Article Influence: 8.2] [Reference Citation Analysis]
191 Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, Bossa F, Cappello M, Castiglione F, Cicala M, Danese S, D’incà R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onali S, Orlando A, Papparella LG, Renna S, Ricci C, Rizzello F, Sostegni R, Guidi L, Papi C. Adalimumab in active ulcerative colitis: A “real-life” observational study. Digestive and Liver Disease 2013;45:738-43. [DOI: 10.1016/j.dld.2013.03.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
192 Feuerstein JD, Akbari M, Tapper EB, Cheifetz AS. Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Ann Gastroenterol 2016;29:341-7. [PMID: 27366036 DOI: 10.20524/aog.2016.0032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
193 Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128. [PMID: 17206703 DOI: 10.1002/ibd.20054] [Cited by in Crossref: 126] [Cited by in F6Publishing: 119] [Article Influence: 8.4] [Reference Citation Analysis]
194 Fasen GS, Pandian TK, Pavey ES, Dozois EJ, Boostrom SY. Long-Term Outcome of IPAA in Patients Presenting with Fulminant Ulcerative Colitis: A Matched Cohort Study. World J Surg 2015;39:2590-4. [DOI: 10.1007/s00268-015-3114-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
195 Danese S, Angelucci E, Malesci A, Caprilli R. Biological agents for ulcerative colitis: hypes and hopes. Med Res Rev. 2008;28:201-218. [PMID: 17464967 DOI: 10.1002/med.20103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
196 Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141-150. [PMID: 27832357 DOI: 10.1007/s00535-016-1283-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
197 Taylor K, Gibson PR. Conventional Therapy of Ulcerative Colitis: Corticosteroids. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Cham: Springer International Publishing; 2017. pp. 399-412. [DOI: 10.1007/978-3-319-33703-6_39] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
198 Jakobovits SL, Travis SP. Management of acute severe colitis. Br Med Bull. 2006;75-76:131-144. [PMID: 16847166 DOI: 10.1093/bmb/ldl001] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
199 Garud S, Peppercorn MA. Ulcerative colitis: current treatment strategies and future prospects. Therap Adv Gastroenterol. 2009;2:99-108. [PMID: 21180538 DOI: 10.1177/1756283x09102329] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
200 Travis S. Advances in therapeutic approaches to ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2005;7:475-484. [PMID: 16313878 DOI: 10.1007/s11894-005-0079-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
201 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
202 Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study. Aliment Pharmacol Ther 2012;35:1301-9. [PMID: 22506582 DOI: 10.1111/j.1365-2036.2012.05099.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
203 Wei X, Gong J, Zhu J, Niu L, Zhu W, Li N, Li J. Therapeutic effects of triptolide on interleukin-10 gene-deficient mice with colitis. International Immunopharmacology 2008;8:1808-12. [DOI: 10.1016/j.intimp.2008.08.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
204 Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, Colombel J, D'haens G, Ghosh S, Marteau P, Kruis W, Mortensen N, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62. [DOI: 10.1016/j.crohns.2007.11.002] [Cited by in Crossref: 378] [Cited by in F6Publishing: 325] [Article Influence: 27.0] [Reference Citation Analysis]
205 Shah SC, Naymagon S, Cohen BL, Sands BE, Dubinsky MC. There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center. J Clin Gastroenterol 2018;52:333-8. [PMID: 28009685 DOI: 10.1097/MCG.0000000000000779] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
206 Ward ST, Mytton J, Henderson L, Amin V, Tanner JR, Evison F, Radley S. Anti-TNF therapy is not associated with an increased risk of post-colectomy complications, a population-based study. Colorectal Dis 2018;20:416-23. [PMID: 29059479 DOI: 10.1111/codi.13937] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
207 Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opinion on Drug Safety 2007;6:479-85. [DOI: 10.1517/14740338.6.5.479] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
208 Nos Mateu P. Nuevos tratamientos y aproximaciones diagnósticas en la colitis ulcerosa. Gastroenterología y Hepatología 2006;29:52-6. [DOI: 10.1157/13098295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
209 Dong C, Metzger M, Holsbø E, Perduca V, Carbonnel F. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. Aliment Pharmacol Ther 2020;51:8-33. [DOI: 10.1111/apt.15592] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
210 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, d'Haens G, d'Hoore A, Mantzanaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, van Assche G. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. Rev Gastroenterol Mex 2015;80:32-73. [PMID: 25769217 DOI: 10.1016/j.rgmx.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
211 Zhang X, Wei L, Wang J, Qin Z, Lu Y, Zheng X, Peng Q, Ye Q, Ai F, Liu P, Wang S, Li G, Shen S, Ma J. Suppression Colitis and Colitis-Associated Colon Cancer by Anti-S100a9 Antibody in Mice. Front Immunol. 2017;8:1774. [PMID: 29326691 DOI: 10.3389/fimmu.2017.01774] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
212 Löwenberg M, Duijvis NW, Ponsioen C, van den Brink GR, Fockens P, D'Haens GR. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis. Eur J Gastroenterol Hepatol 2014;26:1240-6. [PMID: 25171024 DOI: 10.1097/MEG.0000000000000187] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
213 Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8:318-325. [PMID: 24120021 DOI: 10.1016/j.crohns.2013.09.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
214 Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9. [PMID: 25344680 DOI: 10.1093/gastro/gou070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
215 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
216 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
217 Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Anti-tumor necrosis factor and postoperative complications in Crohn’s disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2404-2413. [PMID: 22467533 DOI: 10.1002/ibd.22954] [Cited by in Crossref: 125] [Cited by in F6Publishing: 108] [Article Influence: 12.5] [Reference Citation Analysis]
218 Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010;16:881-895. [PMID: 19885906 DOI: 10.1002/ibd.21154] [Cited by in Crossref: 102] [Cited by in F6Publishing: 78] [Article Influence: 8.5] [Reference Citation Analysis]
219 Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012;59:118-140. [PMID: 22387836 DOI: 10.4166/kjg.2012.59.2.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
220 Kim EH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut Liver 2015;9:601-6. [PMID: 25473080 DOI: 10.5009/gnl14120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
221 Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opinion on Emerging Drugs 2012;17:449-67. [DOI: 10.1517/14728214.2012.744820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
222 Lee JK, Tang DH, Mollon L, Armstrong EP. Cost-effectiveness of biological agents used in ulcerative colitis. Best Pract Res Clin Gastroenterol 2013;27:949-60. [PMID: 24182613 DOI: 10.1016/j.bpg.2013.09.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
223 Lorinczy K, Miheller P, Kiss SL, Lakatos PL. [Epidemiology, predictors and clinical aspects of loss of response to biological therapy]. Orv Hetil 2012;153:163-73. [PMID: 22275731 DOI: 10.1556/OH.2012.29294] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
224 Lakatos L, Lakatos PL. [Medical therapy of inflammatory bowel diseases: ulcerative colitis]. Orv Hetil 2007;148:1163-70. [PMID: 17573252 DOI: 10.1556/OH.2007.28063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
225 Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3516-3524 [PMID: 24707134 DOI: 10.3748/wjg.v20.i13.3516] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
226 Ben Nessib D, Ferjani H, Maatallah K, Rahmouni S, Kaffel D, Hamdi W. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Clin Rheumatol 2020;39:3543-53. [PMID: 32424656 DOI: 10.1007/s10067-020-05136-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
227 Sebastian S, Lisle J, Subramanian S, Dhar A, Shenoy A, Limdi J, Butterworth J, Allen PB, Samuel S, Moran G, Shenderey R, Parkes G, Raine T, Lobo AJ, Kennedy NA. Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterol 2020;11:272-9. [PMID: 32587670 DOI: 10.1136/flgastro-2019-101277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
228 Hosoi K, Ohtsuka Y, Fujii T, Kudo T, Matsunaga N, Tomomasa T, Tajiri H, Kunisaki R, Ishige T, Yamada H, Arai K, Yoden A, Ushijima K, Aomatsu T, Nagata S, Uchida K, Takeuchi K, Shimizu T. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan. J Gastroenterol Hepatol. 2017;32:114-119. [PMID: 27478130 DOI: 10.1111/jgh.13498] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
229 Turner D, Mack D, Leleiko N, Walters TD, Uusoue K, Leach ST, Day AS, Crandall W, Silverberg MS, Markowitz J. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282-2291. [PMID: 20193683 DOI: 10.1053/j.gastro.2010.02.047] [Cited by in Crossref: 164] [Cited by in F6Publishing: 140] [Article Influence: 13.7] [Reference Citation Analysis]
230 Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011;13:475-85. [DOI: 10.1007/s11894-011-0216-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
231 Ho G, Smith L, Aitken S, Lee HM, Ting T, Fennell J, Lees CW, Palmer KR, Penman ID, Shand AG, Arnott ID, Satsangi J. The use of adalimumab in the management of refractory Crohn’s disease: ADALIMUMAB IN REFRACTORY CROHN'S DISEASE. Alimentary Pharmacology & Therapeutics 2008;27:308-15. [DOI: 10.1111/j.1365-2036.2007.03583.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
232 Domènech E. Inflammatory bowel disease: current therapeutic options. Digestion. 2006;73 Suppl 1:67-76. [PMID: 16498254 DOI: 10.1159/000089781] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
233 Peng X, Liu B, Li Y, Wang H, Chen X, Guo H, Guo Q, Xu J, Wang H, Zhang D, Dai J, Hou S, Guo Y. Development and Validation of LC–MS/MS Method for the Quantitation of Infliximab in Human Serum. Chromatographia 2015;78:521-31. [DOI: 10.1007/s10337-015-2866-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
234 Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, Varea V, Domènech E, Badia X. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? Dig Liver Dis. 2007;39:617-625. [PMID: 17531555 DOI: 10.1016/j.dld.2007.03.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
235 Sood A, Midha V, Sharma S, Sood N, Bansal M, Thara A, Khanna P. Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience. Indian J Gastroenterol 2014;33:31-4. [PMID: 23999683 DOI: 10.1007/s12664-013-0372-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
236 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 563] [Article Influence: 170.5] [Reference Citation Analysis]
237 Dayan B, Turner D. Role of surgery in severe ulcerative colitis in the era of medical rescue therapy. World J Gastroenterol 2012; 18(29): 3833-3838 [PMID: 22876035 DOI: 10.3748/wjg.v18.i29.3833] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
238 D'Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 2021;70:1396-405. [PMID: 33431575 DOI: 10.1136/gutjnl-2019-320022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
239 Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, Holmer AK, Nguyen NH, Singh S, Vande Casteele N, Sandborn WJ. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:511-518.e6. [PMID: 32348905 DOI: 10.1016/j.cgh.2020.03.072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
240 Munakata S, Tashiro Y, Nishida C, Sato A, Komiyama H, Shimazu H, Dhahri D, Salama Y, Eiamboonsert S, Takeda K, Yagita H, Tsuda Y, Okada Y, Nakauchi H, Sakamoto K, Heissig B, Hattori K. Inhibition of plasmin protects against colitis in mice by suppressing matrix metalloproteinase 9-mediated cytokine release from myeloid cells. Gastroenterology 2015;148:565-578.e4. [PMID: 25490065 DOI: 10.1053/j.gastro.2014.12.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
241 Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev. 2017;30:191-231. [PMID: 27856521 DOI: 10.1128/cmr.00049-16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
242 Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15-28. [PMID: 21241384 DOI: 10.1111/j.1365-2796.2011.02344.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
243 Fiorino G, Allocca M, Correale C, Roda G, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Danese S. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. Expert Opin Biol Ther 2020;20:421-7. [PMID: 32027523 DOI: 10.1080/14712598.2020.1727437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
244 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 487] [Article Influence: 74.7] [Reference Citation Analysis]
245 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
246 Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6:1112-1116. [PMID: 18928936 DOI: 10.1016/j.cgh.2008.04.035] [Cited by in Crossref: 119] [Cited by in F6Publishing: 93] [Article Influence: 8.5] [Reference Citation Analysis]
247 Strong SA. Management of acute colitis and toxic megacolon. Clin Colon Rectal Surg 2010;23:274-84. [PMID: 22131898 DOI: 10.1055/s-0030-1268254] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
248 Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN. Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. J Crohns Colitis. 2018;. [PMID: 29762697 DOI: 10.1093/ecco-jcc/jjy064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
249 Prosberg MV, Vester-Andersen MK, Andersson M, Jess T, Andersen JT, Vind I, Bendtsen F. Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study. Inflamm Bowel Dis 2016;22:925-32. [PMID: 26818426 DOI: 10.1097/MIB.0000000000000700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
250 Su L, Nalle SC, Shen L, Turner ES, Singh G, Breskin LA, Khramtsova EA, Khramtsova G, Tsai PY, Fu YX, Abraham C, Turner JR. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 2013;145:407-15. [PMID: 23619146 DOI: 10.1053/j.gastro.2013.04.011] [Cited by in Crossref: 192] [Cited by in F6Publishing: 194] [Article Influence: 21.3] [Reference Citation Analysis]
251 Fiorino G, Bonovas S, Cicerone C, Allocca M, Furfaro F, Correale C, Danese S. The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017;16:437-443. [PMID: 28279079 DOI: 10.1080/14740338.2017.1298743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
252 García-Bosch O, Gisbert JP, Cañas-Ventura A, Merino O, Cabriada JL, García-Sánchez V, Gutiérrez A, Nos P, Peñalva M, Hinojosa J, García-Planella E, Muñoz F, Calvet X, Panés J. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013;7:717-22. [PMID: 23142005 DOI: 10.1016/j.crohns.2012.10.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
253 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
255 Caprilli R, Viscido A, Latella G. Current management of severe ulcerative colitis. Nat Rev Gastroenterol Hepatol 2007;4:92-101. [DOI: 10.1038/ncpgasthep0687] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
256 Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011;27:346-57. [PMID: 21654383 DOI: 10.1097/MOG.0b013e328347aef3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
257 Akintimehin AO, O'Neill RS, Ring C, Raftery T, Hussey S. Outcomes of a National Cohort of Children with Acute Severe Ulcerative Colitis. Front Pediatr 2018;6:48. [PMID: 29568735 DOI: 10.3389/fped.2018.00048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
258 Poullenot F, Nivet D, Paul S, Riviere P, Roblin X, Laharie D. Severe endoscopic lesions are not associated with more infliximab fecal loss in acute severe ulcerative colitis. Digestive and Liver Disease 2018;50:1100-3. [DOI: 10.1016/j.dld.2018.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
259 Cohen RD. How should we treat severe acute steroid-refractory ulcerative colitis? Inflamm Bowel Dis. 2009;15:150-151. [PMID: 18844216 DOI: 10.1002/ibd.20776] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
260 Bartels SAL, Gardenbroek TJ, Bos L, Ponsioen CY, D'haens GRAM, Tanis PJ, Buskens CJ, Bemelman WA. Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis. Colorectal Dis 2013;15:1392-8. [DOI: 10.1111/codi.12328] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
261 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
262 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
263 Reenaers C, Louis E, Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:99-106. [PMID: 21180594 DOI: 10.1177/1756283x09356872] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
264 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
265 Sharma R, Sharma* CL. TNF-alpha inhibitors: Current indications. Indian Journal of Critical Care Medicine 2007;11:139-48. [DOI: 10.4103/0972-5229.35087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
266 Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, Boulton-Jones R, Williams A, Church N, Satsangi J. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411-419. [PMID: 17635376 DOI: 10.1111/j.1365-2036.2007.03383.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 6.3] [Reference Citation Analysis]
267 Thorlund K, Druyts E, Toor K, Mills EJ. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol 2015;9:693-700. [PMID: 25763862 DOI: 10.1586/17474124.2015.1024657] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
268 Hatch QM, Ratnaparkhi R, Althans A, Keating M, Neupane R, Nishtala M, Johnson EK, Steele SR. Is Modern Medical Management Changing Ultimate Patient Outcomes in Inflammatory Bowel Disease? J Gastrointest Surg 2016;20:1867-73. [PMID: 27634305 DOI: 10.1007/s11605-016-3275-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
269 Rizzo G, Pugliese D, Armuzzi A, Coco C. Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery? World J Gastroenterol 2014; 20(17): 4839-4845 [PMID: 24803795 DOI: 10.3748/wjg.v20.i17.4839] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
270 Mortensen C, Caspersen S, Christensen NL, Svenningsen L, Thorsgaard N, Christensen LA, Bendtsen F. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. J Crohns Colitis. 2011;5:28-33. [PMID: 21272801 DOI: 10.1016/j.crohns.2010.09.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
271 Hicks CW, Hodin RA, Bordeianou L. Semi-urgent surgery in hospitalized patients with severe ulcerative colitis does not increase overall J-pouch complications. Am J Surg 2014;207:281-7. [PMID: 24112682 DOI: 10.1016/j.amjsurg.2013.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
272 Guo C, Wu K, Liang X, Liang Y, Li R. Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis. Pharmacol Res 2019;148:104455. [PMID: 31562896 DOI: 10.1016/j.phrs.2019.104455] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
273 Leeds IL, Truta B, Parian AM, Chen SY, Efron JE, Gearhart SL, Safar B, Fang SH. Early Surgical Intervention for Acute Ulcerative Colitis Is Associated with Improved Postoperative Outcomes. J Gastrointest Surg. 2017;21:1675-1682. [PMID: 28819916 DOI: 10.1007/s11605-017-3538-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
274 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Peñalva M, Cañas-Ventura A, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Muñoz F, Aguirresarobe M, Muñoz C, Fernández L, Calvet X, Jiménez CE, Montoro MA, Mir A, De Castro ML, García-Sepulcre MF, Bermejo F, Panés J, Esteve M. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol 2017;112:1709-18. [PMID: 28675163 DOI: 10.1038/ajg.2017.180] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
275 Ma C, Beilman CL, Huang VW, Fedorak DK, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Can J Gastroenterol Hepatol 2016;2016:2079582. [PMID: 27478817 DOI: 10.1155/2016/2079582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
276 Chapman CG, Bochenek A, Stein AC, Rubin DT. Use of Serum Infliximab Level Prior to Cyclosporine Salvage Therapy in Severe Ulcerative Colitis. ACG Case Rep J 2014;1:148-50. [PMID: 26157857 DOI: 10.14309/crj.2014.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
277 Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, Mulcahy HE, Cullen G, Doherty GA. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-335. e1. [PMID: 25086187 DOI: 10.1016/j.cgh.2014.07.041] [Cited by in Crossref: 152] [Cited by in F6Publishing: 134] [Article Influence: 19.0] [Reference Citation Analysis]
278 Herrlinger KR, Stange EF, Fellermann K. Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther 2014;14:455-66. [PMID: 24450849 DOI: 10.1517/14712598.2014.880109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
279 Cucchiara S, Morley-fletcher A. “New drugs: Kids come first”: Children should be included in trials of new biological treatments: . Inflammatory Bowel Diseases 2007;13:1165-9. [DOI: 10.1002/ibd.20045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
280 Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of Life After Proctocolectomy With Ileoanal Anastomosis for Patients With Ulcerative Colitis: . Journal of Clinical Gastroenterology 2006;40:669-77. [DOI: 10.1097/00004836-200609000-00002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
281 Feagan BG. Medical Management of Ulcerative Colitis in 2006: What's on the Horizon? Am J Gastroenterology 2007;102:S7-S13. [DOI: 10.1111/j.1572-0241.2007.01292.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
282 Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2016;17:175-84. [DOI: 10.1080/14712598.2017.1271871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
283 Takemoto K, Kato J, Kuriyama M, Nawa T, Kurome M, Okada H, Sakaguchi K, Shiratori Y. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Digestive and Liver Disease 2007;39:422-9. [DOI: 10.1016/j.dld.2007.01.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
284 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
285 Slattery E, Ismail N, Sheridan J, Eustace K, Harewood G, Patchett S. Myocarditis associated with infliximab: A case report and review of the literature. Inflammatory Bowel Diseases 2011;17:1633-4. [DOI: 10.1002/ibd.21546] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
286 Lawrance IC. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. Expert Opin Investig Drugs 2015;24:761-8. [PMID: 25719407 DOI: 10.1517/13543784.2015.1020371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
287 Sands BE. Fulminant Colitis. J Gastrointest Surg 2008;12:2157-9. [DOI: 10.1007/s11605-008-0661-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
288 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
290 Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010;16 Suppl 1:S1-S11. [PMID: 21104734 DOI: 10.1002/ibd.21529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
291 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1450-61. [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 33.5] [Reference Citation Analysis]
292 Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. Front Immunol 2021;12:611256. [PMID: 34079536 DOI: 10.3389/fimmu.2021.611256] [Reference Citation Analysis]
293 Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, Haanen JBAG. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278. [PMID: 29387476 DOI: 10.1136/esmoopen-2017-000278] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 28.0] [Reference Citation Analysis]
294 Johansson M, Norrgård O, Forsgren S. Study of expression patterns and levels of neurotrophins and neurotrophin receptors in ulcerative colitis. Inflamm Bowel Dis. 2007;13:398-409. [PMID: 17206664 DOI: 10.1002/ibd.20072] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
295 Gupta V, Mohsen W, Chapman TP, Satsangi J. Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021. J Crohns Colitis 2021;15:1211-21. [PMID: 33388777 DOI: 10.1093/ecco-jcc/jjaa265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
296 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267-276. [PMID: 21108015 DOI: 10.1007/s11605-010-1396-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
297 Armuzzi A, Pugliese D. IBD: Adalimumab for ulcerative colitis— is the glass half empty or half full? Nat Rev Gastroenterol Hepatol 2011;8:249-51. [PMID: 21423259 DOI: 10.1038/nrgastro.2011.48] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
298 Hanzel J, Almradi A, Istl AC, Yang ML, Fleshner KA, Parker CE, Guizzetti L, Ma C, Singh S, Jairath V. Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis. Dig Dis Sci 2021. [PMID: 33634430 DOI: 10.1007/s10620-021-06895-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Caprilli R. In the case of nonresponse to steroids, what is the second level of treatment in ulcerative colitis? Inflamm Bowel Dis 2008;14 Suppl 2:S226-7. [PMID: 18816754 DOI: 10.1002/ibd.20651] [Reference Citation Analysis]
300 Morilla I, Uzzan M, Laharie D, Cazals-Hatem D, Denost Q, Daniel F, Belleannee G, Bouhnik Y, Wainrib G, Panis Y, Ogier-Denis E, Treton X. Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019;17:905-913. [PMID: 30223112 DOI: 10.1016/j.cgh.2018.08.068] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
301 Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011;17:831-848. [PMID: 21319274 DOI: 10.1002/ibd.21375] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 7.4] [Reference Citation Analysis]
302 Di Sabatino A, Liberato L, Marchetti M, Biancheri P, Corazza GR. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6 Suppl 1:17-27. [PMID: 22009609 DOI: 10.1007/s11739-011-0673-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
303 Klair JS, Girotra M, Hutchins LF, Caradine KD, Aduli F, Garcia-Saenz-de-Sicilia M. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. Dig Dis Sci. 2016;61:2132-2139. [PMID: 26846115 DOI: 10.1007/s10620-016-4042-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
304 Thukral C, Cheifetz A, Peppercorn MA. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs 2006;66:2059-65. [PMID: 17112300 DOI: 10.2165/00003495-200666160-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
305 Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol 2016;9:548-59. [PMID: 27366223 DOI: 10.1177/1756283X16643242] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
306 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
307 Sobrado CW, Sobrado LF. MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. Arq Bras Cir Dig 2016;29:201-5. [PMID: 27759787 DOI: 10.1590/0102-6720201600030017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
308 D'Haens G. Anti-TNF-alpha treatment strategies: results and clinical perspectives. Gastroenterol Clin Biol 2009;33 Suppl 3:S209-16. [PMID: 20117344 DOI: 10.1016/S0399-8320(09)73156-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
309 Teisner AS, Ainsworth MA, Brynskov J. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience. Scand J Gastroenterol. 2010;45:1457-1463. [PMID: 20701434 DOI: 10.3109/00365521.2010.510572] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
310 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
311 Latella G, Fiocchi C, Caprilli R. Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006. Inflamm Bowel Dis 2007;13:1031-50. [PMID: 17309072 DOI: 10.1002/ibd.20127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
312 Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 2007;7:13. [PMID: 17389040 DOI: 10.1186/1471-230x-7-13] [Cited by in Crossref: 63] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
313 Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2009;15:935-950. [PMID: 18985710 DOI: 10.1002/ibd.20797] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
314 Lau A, Chande N, Ponich T, Gregor JC. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2008;28:606-613. [PMID: 18564323 DOI: 10.1111/j.1365-2036.2008.03772.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
315 Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther. 2013;38:294-302. [PMID: 23786158 DOI: 10.1111/apt.12375] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 7.3] [Reference Citation Analysis]
316 Melgar S, Karlsson L, Rehnström E, Karlsson A, Utkovic H, Jansson L, Michaëlsson E. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int Immunopharmacol. 2008;8:836-844. [PMID: 18442787 DOI: 10.1016/j.intimp.2008.01.036] [Cited by in Crossref: 131] [Cited by in F6Publishing: 133] [Article Influence: 9.4] [Reference Citation Analysis]
317 Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci. 2011;7:1000-1012. [PMID: 22328883 DOI: 10.5114/aoms.2011.26612] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
318 Takeuchi I, Kaburaki Y, Arai K, Shimizu H, Hirano Y, Nagata S, Shimizu T. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan. J Gastroenterol Hepatol 2020;35:593-600. [PMID: 31425641 DOI: 10.1111/jgh.14836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
319 D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212; quiz 213. [PMID: 21045814 DOI: 10.1038/ajg.2010.392] [Cited by in Crossref: 263] [Cited by in F6Publishing: 256] [Article Influence: 21.9] [Reference Citation Analysis]
320 Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
321 Ganzleben I, Geppert C, Osaba L, Hirschmann S, Nägel A, Glück C, Hoffman A, Rath T, Nagore D, Neurath MF, Atreya R. Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820954112. [PMID: 33101457 DOI: 10.1177/1756284820954112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
322 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
323 Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811-1819. [PMID: 20197757 DOI: 10.1038/ajg.2010.95] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 9.2] [Reference Citation Analysis]
324 Daniel F, Loriot MA, Seksik P, Cosnes J, Gornet JM, Lémann M, Fein F, Vernier-Massouille G, De Vos M, Boureille A. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007;13:19-23. [PMID: 17206635 DOI: 10.1002/ibd.20046] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
325 Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009;623 Suppl 1:S17-25. [PMID: 19837056 DOI: 10.1016/j.ejphar.2009.10.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
326 Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol 2015;13:336-8. [PMID: 25285408 DOI: 10.1016/j.cgh.2014.09.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
327 Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944-948. [PMID: 18028512 DOI: 10.1111/j.1572-0241.2007.01638.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 117] [Article Influence: 7.9] [Reference Citation Analysis]
328 Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68:1157-1167. [PMID: 18547130 DOI: 10.2165/00003495-200868090-00001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
329 Mocciaro F, Renna S, Orlando A, Rizzuto G, Sinagra E, Orlando E, Cottone M. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis. 2012;6:681-686. [PMID: 22398101 DOI: 10.1016/j.crohns.2011.11.021] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
330 Dahlén R, Strid H, Lundgren A, Isaksson S, Raghavan S, Magnusson MK, Simrén M, Sjövall H, Öhman L. Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis. Scand J Immunol. 2013;78:275-284. [PMID: 23713660 DOI: 10.1111/sji.12081] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
331 Bennis M, Tiret E. Surgical management of ulcerative colitis. Langenbecks Arch Surg. 2012;397:11-17. [PMID: 21922296 DOI: 10.1007/s00423-011-0848-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
332 Sedano R, Quera R, Simian D, Yarur AJ. An approach to acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:943-55. [PMID: 31648574 DOI: 10.1080/17474124.2019.1681974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
333 Coquet-Reinier B, Berdah SV, Grimaud JC, Birnbaum D, Cougard PA, Barthet M, Desjeux A, Moutardier V, Brunet C. Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg Endosc. 2010;24:1866-1871. [PMID: 20108148 DOI: 10.1007/s00464-009-0861-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
334 Teixeira FV, Hosne RS, Sobrado CW. Management of ulcerative colitis: a clinical update. Journal of Coloproctology 2021;35:230-7. [DOI: 10.1016/j.jcol.2015.08.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
335 Xu Y, Dong H, Ge C, Gao Y, Liu H, Li W, Zhang C. CBLB502 administration protects gut mucosal tissue in ulcerative colitis by inhibiting inflammation. Ann Transl Med 2016;4:301. [PMID: 27668221 DOI: 10.21037/atm.2016.08.25] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
336 Deiana S, Bagnoli S, Manetti N, Caini S, Giannotta M, Scaringi S, Annese V. Outcome of acute severe ulcerative colitis in patients previously exposed to immunosuppressive therapy. Digestive and Liver Disease 2016;48:1432-7. [DOI: 10.1016/j.dld.2016.07.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
337 Mawdsley JE, Macey MG, Feakins RM, Langmead L, Rampton DS. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology. 2006;131:410-419. [PMID: 16890594 DOI: 10.1053/j.gastro.2006.05.017] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 5.3] [Reference Citation Analysis]
338 Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: When? How? Best Practice & Research Clinical Gastroenterology 2018;32-33:71-8. [DOI: 10.1016/j.bpg.2018.05.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
339 Szemes K, Soós A, Hegyi P, Farkas N, Erős A, Erőss B, Mezősi E, Szakács Z, Márta K, Sarlós P. Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis. Front Med (Lausanne) 2019;6:338. [PMID: 32039218 DOI: 10.3389/fmed.2019.00338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
340 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
341 Florholmen J, Øverland G, Olsen T, Rismo R, Cui G, Christiansen I, Paulssen EJ, Goll R. Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis. Ulcers 2011;2011:1-7. [DOI: 10.1155/2011/156407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
342 Govani SM, Berinstein JA, Waljee AK, Stidham RW, Higgins PDR, Hardiman KM. Use of Accelerated Induction Strategy of Infliximab for Ulcerative Colitis in Hospitalized Patients at a Tertiary Care Center. Dig Dis Sci 2020;65:1800-5. [DOI: 10.1007/s10620-019-05957-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
343 Barreiro-de Acosta M, Gisbert JP. Letter: surgery for ulcerative colitis mostly follows anti-TNF drugs--a new 'therapeutic package'? Aliment Pharmacol Ther 2012;36:297-8; author reply 298-9. [PMID: 22747458 DOI: 10.1111/j.1365-2036.2012.05158.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
344 Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opinion on Biological Therapy 2006;6:401-8. [DOI: 10.1517/14712598.6.4.401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
345 Ho G, Boyapati R, Satsangi J. Ulcerative colitis. Medicine 2015;43:276-81. [DOI: 10.1016/j.mpmed.2015.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
346 Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
347 Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688. [PMID: 18532990 DOI: 10.1111/j.1365-2036.2008.03753.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
348 Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, Mathôt RA, Ponsioen CY, Löwenberg M, D’haens GR. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology 2015;149:350-355.e2. [DOI: 10.1053/j.gastro.2015.04.016] [Cited by in Crossref: 237] [Cited by in F6Publishing: 198] [Article Influence: 33.9] [Reference Citation Analysis]
349 Brazilian Study Group of Inflammatory Bowel Diseases. Consensus guidelines for the management of inflammatory bowel disease. Arq Gastroenterol. 2010;47:313-325. [PMID: 21140096 DOI: 10.1590/s0004-28032010000300019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
350 Matsumoto S, Kawamura H, Nishikawa T, Sagihara N, Miyatani H, Mashima H. Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. Clin Exp Gastroenterol 2017;10:249-58. [PMID: 29026326 DOI: 10.2147/CEG.S143224] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
351 Tiemi J, Komati S, Sdepanian VL. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. J Pediatr Gastroenterol Nutr 2010;50:628-33. [PMID: 20386321 DOI: 10.1097/MPG.0b013e3181bbf481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
352 Xie T, Zhao C, Ding C, Zhang T, Dai X, Lv T, Li Y, Guo Z, Gong J, Zhu W. Fecal calprotectin as an alternative to ulcerative colitis endoscopic index of severity to predict the response to corticosteroids of acute severe ulcerative colitis: A prospective observational study. Dig Liver Dis. 2017;49:984-990. [PMID: 28539226 DOI: 10.1016/j.dld.2017.04.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
353 Nishida Y, Hosomi S, Yamagami H, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Tominaga K, Fujiwara Y. Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. PLoS One. 2017;12:e0169845. [PMID: 28076386 DOI: 10.1371/journal.pone.0169845] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
354 Sandborn WJ. Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience. Inflamm Bowel Dis 2008;14 Suppl 2:S232-3. [PMID: 18816658 DOI: 10.1002/ibd.20674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
355 Maldonado-Pérez MB, Castro-Laria L, Caunedo-Álvarez A, Montoya-García MJ, Giner-García M, Argüelles-Arias F, Romero-Gómez M, Vázquez-Gámez MÁ. Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease? J Clin Densitom 2019;22:195-202. [PMID: 30205986 DOI: 10.1016/j.jocd.2018.07.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
356 Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015;47:356-364. [PMID: 25661014 DOI: 10.1016/j.dld.2015.01.148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
357 Hossain A, Lördal M, Olsson AE, Storlåhls A, Aleman S, Eberhardson M, Befrits R. Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease. Scand J Gastroenterol 2020;55:178-83. [PMID: 32052663 DOI: 10.1080/00365521.2020.1722738] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
358 Fernández-salazar L, Muñoz F, Barrio J, Muñoz C, Pajares R, Rivero M, Prieto V, Legido J, Bouhmidi A, Herranz M, Fernández N, Sánchez-ocaña R, Joao D, Santos F. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study). Scandinavian Journal of Gastroenterology 2015;51:186-95. [DOI: 10.3109/00365521.2015.1070900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
359 Kulaylat AS, Kulaylat AN, Schaefer EW, Tinsley A, Williams E, Koltun W, Hollenbeak CS, Messaris E. Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis. JAMA Surg 2017;152:e171538. [PMID: 28614561 DOI: 10.1001/jamasurg.2017.1538] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
360 Venkateswaran N, Weismiller S, Clarke K. Indeterminate Colitis - Update on Treatment Options. J Inflamm Res 2021;14:6383-95. [PMID: 34876831 DOI: 10.2147/JIR.S268262] [Reference Citation Analysis]
361 Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
362 Subramaniam K, Richardson A, Dodd J, Platten J, Shadbolt B, Pavli P. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy: Anti-TNF therapy in ulcerative colitis. Intern Med J 2014;44:464-70. [DOI: 10.1111/imj.12397] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
363 Lynch RW, Churchhouse AMD, Protheroe A, Arnott IDR; the UK IBD Audit Steering Group. Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data. Aliment Pharmacol Ther 2016;43:1132-41. [DOI: 10.1111/apt.13614] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
364 Peyrin-biroulet L. Que deviennent les colites aiguës graves traitées médicalement avec succès? Colon Rectum 2008;2:17-21. [DOI: 10.1007/s11725-008-0072-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
365 Evans PE, Pardi DS. Inflammatory bowel disease in the elderly. Aging Health 2007;3:77-84. [DOI: 10.2217/1745509x.3.1.77] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
366 Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228-1235. [PMID: 22613902 DOI: 10.1038/ajg.2012.127] [Cited by in Crossref: 179] [Cited by in F6Publishing: 164] [Article Influence: 17.9] [Reference Citation Analysis]
367 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 46.0] [Reference Citation Analysis]
368 Zhou Y, Huang Y. Inflammatory bowel disease in Chinese children: A retrospective analysis of 49 cases. Exp Ther Med 2016;12:3363-8. [PMID: 27882164 DOI: 10.3892/etm.2016.3756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
369 Minami N, Yoshino T, Matsuura M, Koshikawa Y, Yamada S, Toyonaga T, Madian A, Honzawa Y, Nakase H. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2015;2:e000021. [PMID: 26462273 DOI: 10.1136/bmjgast-2014-000021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
370 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
371 Vogel H, Halpert D, Horoupian DS. Hypoplasia of posterior spinal roots and dorsal spinal tracts with arthrogryposis multiplex congenita. Acta Neuropathol. 1990;79:692-696. [PMID: 2360413 DOI: 10.1136/gutjnl-2013-304636] [Cited by in Crossref: 221] [Cited by in F6Publishing: 196] [Article Influence: 6.9] [Reference Citation Analysis]
372 Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver 2015;9:18-27. [PMID: 25547087 DOI: 10.5009/gnl14226] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
373 Targownik LE, Tennakoon A, Leung S, Lix LM, Nugent Z, Singh H, Bernstein CN. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis. Inflammatory Bowel Diseases 2017;23:409-20. [DOI: 10.1097/mib.0000000000001025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
374 Levesque BG, Sandborn WJ. Infliximab versus ciclosporin in severe ulcerative colitis. Lancet 2012;380:1887-8. [PMID: 23063315 DOI: 10.1016/S0140-6736(12)61259-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
375 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
376 Gearry RB, Falvey JD. Rescue therapy for steroid refractory acute severe ulcerative colitis: more choice, better outcomes? J Gastroenterol Hepatol 2012;27:417-8. [PMID: 22353345 DOI: 10.1111/j.1440-1746.2012.07063.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
377 Clark M, Colombel J, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology 2007;133:312-39. [DOI: 10.1053/j.gastro.2007.05.006] [Cited by in Crossref: 157] [Cited by in F6Publishing: 145] [Article Influence: 10.5] [Reference Citation Analysis]
378 Ho G, Lees C, Satsangi J. Ulcerative colitis. Medicine 2007;35:277-82. [DOI: 10.1016/j.mpmed.2007.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
379 Sasaki M, Sitaraman SV, Babbin BA, Gerner-Smidt P, Ribot EM, Garrett N, Alpern JA, Akyildiz A, Theiss AL, Nusrat A, Klapproth JM. Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest. 2007;87:1042-1054. [PMID: 17660846 DOI: 10.1038/labinvest.3700661] [Cited by in Crossref: 155] [Cited by in F6Publishing: 161] [Article Influence: 10.3] [Reference Citation Analysis]
380 Padovan M, Castellino G, Govoni M, Trotta F. The treatment of the rheumatological manifestations of the inflammatory bowel diseases. Rheumatol Int 2006;26:953-8. [DOI: 10.1007/s00296-006-0148-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
381 Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1385-1397. e10. [PMID: 27189910 DOI: 10.1016/j.cgh.2016.04.039] [Cited by in Crossref: 179] [Cited by in F6Publishing: 159] [Article Influence: 29.8] [Reference Citation Analysis]
382 Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Expert Opinion on Drug Safety 2014;13:1749-62. [DOI: 10.1517/14740338.2014.959489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
383 Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094-1103. [PMID: 25809869 DOI: 10.1111/apt.13175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
384 Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies. Aliment Pharmacol Ther. 2007;25:111-122. [PMID: 17229236 DOI: 10.1111/j.1365-2036.2006.03156.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
385 Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:949-59. [PMID: 31665288 DOI: 10.1093/ibd/izz244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
386 Kevans D, Murthy S, Mould DR, Silverberg MS. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. Journal of Crohn's and Colitis 2018;12:662-9. [DOI: 10.1093/ecco-jcc/jjy028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
387 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
388 Ng SC, Kamm MA. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics 2008;28:815-29. [DOI: 10.1111/j.1365-2036.2008.03800.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
389 Atreya R, Neumann H, Neurath MF. [Rational treatment of ulcerative colitis--local or systemic therapy? Surgery?]. MMW Fortschr Med 2012;154:76-8. [PMID: 22957389 DOI: 10.1007/s15006-012-0934-1] [Reference Citation Analysis]
390 Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis. 2010;16:1898-1904. [PMID: 20310016 DOI: 10.1002/ibd.21259] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
391 Jiang W, Zhang SC. New strategies in therapy for inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2008; 16(22): 2497-2502 [DOI: 10.11569/wcjd.v16.i22.2497] [Reference Citation Analysis]
392 Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011;46:129-137. [PMID: 21132334 DOI: 10.1007/s00535-010-0352-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
393 Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007;133:1414-1422. [PMID: 17920064 DOI: 10.1053/j.gastro.2007.08.035] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
394 Tamboli CP. Current Medical Therapy for Chronic Inflammatory Bowel Diseases. Surgical Clinics of North America 2007;87:697-725. [DOI: 10.1016/j.suc.2007.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
395 Assche GV, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol 2008; 14(36): 5508-5511 [PMID: 18810767 DOI: 10.3748/wjg.14.5508] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
396 Rolny P, Vatn M. Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article. Scand J Gastroenterol 2013;48:131-5. [PMID: 23110487 DOI: 10.3109/00365521.2012.733954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
397 Kin C, Kate Bundorf M. As Infliximab Use for Ulcerative Colitis Has Increased, so Has the Rate of Surgical Resection. J Gastrointest Surg 2017;21:1159-65. [PMID: 28484890 DOI: 10.1007/s11605-017-3431-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
398 Park SH, Kim YM, Yang SK, Kim SH, Byeon JS, Myung SJ, Cho YK, Yu CS, Choi KS, Chung JW. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007;13:278-283. [PMID: 17206722 DOI: 10.1002/ibd.20015] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 5.9] [Reference Citation Analysis]
399 Goodman WA, Basavarajappa SC, Liu AR, Rodriguez FDS, Mathes T, Ramakrishnan P. Sam68 contributes to intestinal inflammation in experimental and human colitis. Cell Mol Life Sci 2021. [PMID: 34693458 DOI: 10.1007/s00018-021-03976-7] [Reference Citation Analysis]
400 Moore SE, McGrail KM, Peterson S, Raval MJ, Karimuddin AA, Phang PT, Bressler B, Brown CJ. Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum 2014;57:83-90. [PMID: 24316950 DOI: 10.1097/DCR.0000000000000003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
401 Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407. [PMID: 16819502 DOI: 10.1038/ncpgasthep0528] [Cited by in Crossref: 1075] [Cited by in F6Publishing: 1022] [Article Influence: 67.2] [Reference Citation Analysis]
402 Piton G, Dupont-Gossart AC, Weber A, Herbein G, Viennet G, Mantion G, Carbonnel F. Severe systemic cytomegalovirus infections in patients with steroid-refractory ulcerative colitis treated by an oral microemulsion form of cyclosporine: report of two cases. Gastroenterol Clin Biol 2008;32:460-4. [PMID: 18359591 DOI: 10.1016/j.gcb.2007.10.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
403 Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. Gastroenterology 2009;137:1250-60. [DOI: 10.1053/j.gastro.2009.06.061] [Cited by in Crossref: 312] [Cited by in F6Publishing: 291] [Article Influence: 24.0] [Reference Citation Analysis]
404 Llaó J, Naves JE, Ruiz-Cerulla A, Gordillo J, Mañosa M, Maisterra S, Cabré E, Garcia-Planella E, Guardiola J, Domènech E. Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies. Dig Liver Dis 2016;48:608-12. [PMID: 27012443 DOI: 10.1016/j.dld.2016.02.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
405 Ellis MC, Diggs BS, Vetto JT, Herzig DO. Trends in the surgical treatment of ulcerative colitis over time: increased mortality and centralization of care. World J Surg. 2011;35:671-676. [PMID: 21165620 DOI: 10.1007/s00268-010-0910-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
406 Turner D, Travis SP, Griffiths AM, Ruemmele FM, Levine A, Benchimol EI, Dubinsky M, Alex G, Baldassano RN, Langer JC. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011;106:574-588. [PMID: 21224839 DOI: 10.1038/ajg.2010.481] [Cited by in Crossref: 140] [Cited by in F6Publishing: 107] [Article Influence: 12.7] [Reference Citation Analysis]
407 Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, Shand AG, Bartolo DC, Wilson RG, Dunlop MG. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673-678. [PMID: 19262524 DOI: 10.1038/ajg.2008.119] [Cited by in Crossref: 97] [Cited by in F6Publishing: 97] [Article Influence: 7.5] [Reference Citation Analysis]
408 Nishida Y, Hosomi S, Watanabe K, Watanabe K, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Yamagami H, Tanigawa T, Watanabe T, Fujiwara Y. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scand J Gastroenterol 2018;53:579-85. [PMID: 29171305 DOI: 10.1080/00365521.2017.1403647] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
409 Weber A, Fein F, Koch S, Dupont-gossart A, Mantion G, Heyd B, Carbonnel F. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral): . Inflammatory Bowel Diseases 2006;12:1131-5. [DOI: 10.1097/01.mib.0000235096.78736.8e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
410 Rönnblom A, Karlbom U. Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort. Scand J Gastroenterol 2021;56:403-9. [PMID: 33577739 DOI: 10.1080/00365521.2021.1882553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
411 Oh SJ, Shin GY, Soh H, Lee JG, Im JP, Eun CS, Lee KM, Park DI, Han DS, Kim HJ, Lee CK. Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. Intest Res 2021;19:323-31. [PMID: 32806875 DOI: 10.5217/ir.2020.00039] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
412 Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680-687. [PMID: 18242604 DOI: 10.1053/j.gastro.2008.01.004] [Cited by in Crossref: 195] [Cited by in F6Publishing: 175] [Article Influence: 13.9] [Reference Citation Analysis]
413 Ho G, Lees C, Satsangi J. Ulcerative colitis. Medicine 2011;39:224-8. [DOI: 10.1016/j.mpmed.2011.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
414 Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;CD005112. [PMID: 16856078 DOI: 10.1002/14651858.cd005112.pub2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
415 Ahirwar DK, Kesarwani P, Singh R, Ghoshal UC, Mittal RD. Role of tumor necrosis factor-alpha (C-863A) polymorphism in pathogenesis of inflammatory bowel disease in Northern India. J Gastrointest Cancer. 2012;43:196-204. [PMID: 21249467 DOI: 10.1007/s12029-010-9238-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
416 Teixeira FV, Vilela EG, Damião AOMC, Vieira A, Albuquerque IC, Parente JML, Chebli JMF, Ambrogini Junior O, Hossne RS, Miszputen SJ. Ulcerative colitis - treatment with biologicals. Rev Assoc Med Bras (1992) 2019;65:547-53. [PMID: 31066808 DOI: 10.1590/1806-9282.65.4.547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
417 Mares WG, Gerver J, Masclee AA, Pierik M. Anti-TNF treatment of ulcerative colitis associated with idiopathic thrombocytopenic purpura. Inflamm Bowel Dis. 2011;17:864-865. [PMID: 20848499 DOI: 10.1002/ibd.21327] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
418 Poppers DM, Scherl EJ. Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care. Inflamm Bowel Dis. 2008;14:106-113. [PMID: 17886285 DOI: 10.1002/ibd.20261] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
419 Halfvarson J, Järnerot G. Treatment of choice for acute severe steroid-refractory ulcerative colitis is Remicade: . Inflammatory Bowel Diseases 2009;15:143-5. [DOI: 10.1002/ibd.20782] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
420 Hosseini SV, Jafari P, Taghavi SA, Safarpour AR, Rezaianzadeh A, Moini M, Mehrabi M. Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis. Iran Red Crescent Med J 2015;17:e22796. [PMID: 25793117 DOI: 10.5812/ircmj.22796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
421 Rostholder E, Ahmed A, Cheifetz AS, Moss AC. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther. 2012;35:562-567. [PMID: 22239070 DOI: 10.1111/j.1365-2036.2011.04986.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
422 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Beaugerie L, Ricart E, Dewit O, Lopez-sanroman A, Fumery M, Carbonnel F, Buisson A, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Peyrin-biroulet L, Mary J. Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clinical Gastroenterology and Hepatology 2021;19:1180-1188.e4. [DOI: 10.1016/j.cgh.2020.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
423 Li XX, Chen SG, Yue GG, Kwok HF, Lee JK, Zheng T, Shaw PC, Simmonds MSJ, Lau CB. Natural flavone tricin exerted anti-inflammatory activity in macrophage via NF-κB pathway and ameliorated acute colitis in mice. Phytomedicine 2021;90:153625. [PMID: 34256329 DOI: 10.1016/j.phymed.2021.153625] [Reference Citation Analysis]
424 Braun F, Behrend M. Basic immunosuppressive drugs outside solid organ transplantation. Expert Opin Investig Drugs 2006;15:267-91. [PMID: 16503764 DOI: 10.1517/13543784.15.3.267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
425 Hussey M, Mc Garrigle R, Kennedy U, Holleran G, Kevans D, Ryan B, Breslin N, Mahmud N, McNamara D. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis. Eur J Gastroenterol Hepatol. 2016;28:217-221. [PMID: 26587866 DOI: 10.1097/meg.0000000000000515] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
426 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
427 Mañosa M, Cabré E, Garcia-planella E, Bernal I, Gordillo J, Esteve M, Zabana Y, Gassull MA, Domènech E. Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids: . Inflammatory Bowel Diseases 2011;17:2497-502. [DOI: 10.1002/ibd.21634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
428 Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc 2009;7:20. [PMID: 20003364 DOI: 10.1186/1478-7547-7-20] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
429 Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, Oliveira L, Plamondon S, Seow CH, Williams C. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28:275-285. [PMID: 24839622 DOI: 10.1155/2014/941245] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
430 Bernal I, Mañosa M, Domènech E, Garcia-Planella E, Navarro M, Lorenzo-Zúñiga V, Cabré E, Gassull MA. Predictors of clinical response to systemic steroids in active ulcerative colitis. Dig Dis Sci 2006;51:1434-8. [PMID: 16868820 DOI: 10.1007/s10620-006-9103-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
431 Abou Khalil M, Boutros M, Nedjar H, Morin N, Ghitulescu G, Vasilevsky CA, Gordon P, Rahme E. Incidence Rates and Predictors of Colectomy for Ulcerative Colitis in the Era of Biologics: Results from a Provincial Database. J Gastrointest Surg 2018;22:124-32. [PMID: 28808892 DOI: 10.1007/s11605-017-3530-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
432 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
433 Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210. [PMID: 21552489 DOI: 10.2147/dddt.s11290] [Cited by in Crossref: 137] [Cited by in F6Publishing: 76] [Article Influence: 12.5] [Reference Citation Analysis]
434 Weber CR, Raleigh DR, Su L, Shen L, Sullivan EA, Wang Y, Turner JR. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem. 2010;285:12037-12046. [PMID: 20177070 DOI: 10.1074/jbc.m109.064808] [Cited by in Crossref: 174] [Cited by in F6Publishing: 126] [Article Influence: 14.5] [Reference Citation Analysis]
435 Berinstein JA, Steiner CA, Higgins PDR. Reply. Clin Gastroenterol Hepatol 2021;19:1303-4. [PMID: 33248182 DOI: 10.1016/j.cgh.2020.08.023] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
436 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Fumery M, Carbonnel F, Bommelaer G, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Lambert J, Mary JY, Louis E; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018;67:237-43. [PMID: 28053054 DOI: 10.1136/gutjnl-2016-313060] [Cited by in F6Publishing: 58] [Reference Citation Analysis]
437 Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Koutroubakis IE. Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:1266-71. [PMID: 29718260 DOI: 10.1093/ibd/izy088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
438 Kim MJ, Kim E, Kang B, Choe YH. Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy. Yonsei Med J 2021;62:608-14. [PMID: 34164958 DOI: 10.3349/ymj.2021.62.7.608] [Reference Citation Analysis]
439 Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114-126. [PMID: 25488896 DOI: 10.1038/ajg.2014.357] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 13.9] [Reference Citation Analysis]
440 Peyrin-biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease: Review: remission rates in IBD. Alimentary Pharmacology & Therapeutics 2011;33:870-9. [DOI: 10.1111/j.1365-2036.2011.04599.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 9.5] [Reference Citation Analysis]
441 Zisman TL, Kane SV. Current and future therapies for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2007;1:89-100. [PMID: 19072438 DOI: 10.1586/17474124.1.1.89] [Reference Citation Analysis]
442 Kugathasan S, Dubinsky MC, Keljo D, Moyer MS, Rufo PA, Wyllie R, Zachos M, Hyams J. Severe Colitis in Children: . Journal of Pediatric Gastroenterology and Nutrition 2005;41:375-85. [DOI: 10.1097/01.mpg.0000186272.65559.ce] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
443 Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182-1197. [PMID: 19249397 DOI: 10.1053/j.gastro.2009.02.001] [Cited by in Crossref: 267] [Cited by in F6Publishing: 252] [Article Influence: 20.5] [Reference Citation Analysis]
444 Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis. Expert Opin Pharmacother 2006;7:1907-18. [PMID: 17020417 DOI: 10.1517/14656566.7.14.1907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
445 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
446 Kayal M, Saha A, Poojary P, Paramsothy S, Hirten R, Cohen L, Gallinger Z, Mehandru S, Cho J, Greenstein A, Nadkarni G, Dubinsky MC, Colombel JF, Cohen B, Ungaro R. Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. Int J Colorectal Dis 2019;34:1771-9. [PMID: 31512019 DOI: 10.1007/s00384-019-03375-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
447 Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60. [PMID: 17655372 DOI: 10.2165/00003088-200746080-00002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 11.1] [Reference Citation Analysis]
448 Zanelli J, Chandrapalan S, Patel A, Arasaradnam RP. The impact of pre-operative biologic therapy on post-operative surgical outcomes in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820937089. [PMID: 33281933 DOI: 10.1177/1756284820937089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
449 Díez M, Sánchez E, García López S, Teresa Arroyo M, Gomollón F. Tratamiento con infliximab en la colitis ulcerosa: experiencia inicial en dos centros de referencia. Gastroenterología y Hepatología 2007;30:449-53. [DOI: 10.1157/13110489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
450 Song Y, Zheng P. Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials. Journal of Food and Drug Analysis 2015;23:1-10. [DOI: 10.1016/j.jfda.2014.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
451 Brown SR, Haboubi N, Hampton J, George B, Travis SP. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008;10 Suppl 3:8-29. [PMID: 18954307 DOI: 10.1111/j.1463-1318.2008.01682.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
452 Hanauer SB. Infliximab or Cyclosporine for Severe Ulcerative Colitis. Gastroenterology 2005;129:1358-9. [DOI: 10.1053/j.gastro.2005.08.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
453 Costa J, Magro F, Caldeira D, Alarcão J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013;19:2098-110. [PMID: 23860567 DOI: 10.1097/MIB.0b013e31829936c2] [Cited by in Crossref: 75] [Cited by in F6Publishing: 27] [Article Influence: 9.4] [Reference Citation Analysis]
454 Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20:451-471. [PMID: 16777576 DOI: 10.1016/j.berh.2006.03.010] [Cited by in Crossref: 117] [Cited by in F6Publishing: 99] [Article Influence: 7.3] [Reference Citation Analysis]
455 Joo M, Odze RD. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy. Am J Surg Pathol. 2010;34:689-696. [PMID: 20410806 DOI: 10.1097/pas.0b013e3181db84cd] [Cited by in Crossref: 58] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
456 Schwanke RC, Marcon R, Bento AF, Calixto JB. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. Eur J Pharmacol 2016;785:156-64. [PMID: 26325092 DOI: 10.1016/j.ejphar.2015.08.050] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
457 Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12(29): 4628-4635 [PMID: 16937430 DOI: 10.3748/wjg.v12.i29.4628] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
458 O'Connor JP, O'Moráin CA, Neary P, Breslin NP. Use of Infliximab as rescue therapy in acute severe Ulcerative Colitis with recent norovirus infection. J Crohns Colitis 2009;3:204-6. [PMID: 21172272 DOI: 10.1016/j.crohns.2009.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
459 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
460 Joos S, Wildau N, Kohnen R, Szecsenyi J, Schuppan D, Willich SN, Hahn EG, Brinkhaus B. Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol. 2006;41:1056-1063. [PMID: 16938719 DOI: 10.1080/00365520600580688] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
461 Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2009;44:727-735. [PMID: 19294580 DOI: 10.1080/00365520902803507] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
462 Kelly OB, Rosenberg M, Tyler AD, Stempak JM, Steinhart AH, Cohen Z, Greenberg GR, Silverberg MS. Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis. J Crohns Colitis 2016;10:410-7. [PMID: 26721938 DOI: 10.1093/ecco-jcc/jjv225] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
463 Chiorean MV, Pokhrel B, Adabala J, Helper DJ, Johnson CS, Juliar B. Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci 2011;56:1489-95. [PMID: 20953706 DOI: 10.1007/s10620-010-1430-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
464 Goldstein N, Dulai M. Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease. Am J Clin Pathol. 2006;126:365-376. [PMID: 16880149 DOI: 10.1309/uaxmw3428pgn9hj3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
465 Treton X, Laharie D. Prise en charge d’une colite aiguë grave. Gastroentérologie Clinique et Biologique 2008;32:1030-7. [DOI: 10.1016/j.gcb.2008.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
466 Straughan DM, McLoughlin KC, Mullinax JE, Marciano BE, Freeman AF, Anderson VL, Uzel G, Azoury SC, Sorber R, Quadri HS, Malech HL, DeRavin SS, Kamal N, Koh C, Zerbe CS, Kuhns DB, Gallin JI, Heller T, Holland SM, Rudloff U. The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease. Clin Infect Dis 2018;66:1427-34. [PMID: 29145578 DOI: 10.1093/cid/cix1012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
467 Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5(4): 579-588 [PMID: 25401001 DOI: 10.4291/wjgp.v5.i4.579] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
468 Kucharzik T, Maaser C, Lügering A, Kagnoff M, Mayer L, Targan S, Domschke W. Recent understanding of IBD pathogenesis: Implications for future therapies: . Inflammatory Bowel Diseases 2006;12:1068-83. [DOI: 10.1097/01.mib.0000235827.21778.d5] [Cited by in Crossref: 161] [Cited by in F6Publishing: 158] [Article Influence: 10.1] [Reference Citation Analysis]
469 Shi YH, Weng Y, Liu ZJ. Detection of serum infliximab concentration for evaluation of treatment efficacy in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2015; 23(31): 4946-4953 [DOI: 10.11569/wcjd.v23.i31.4946] [Reference Citation Analysis]
470 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 64] [Cited by in F6Publishing: 21] [Article Influence: 21.3] [Reference Citation Analysis]
471 Annese V, Duricova D, Gower-rousseau C, Jess T, Langholz E. Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. ECCOJC 2016;10:216-25. [DOI: 10.1093/ecco-jcc/jjv190] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
472 de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:3-14. [PMID: 17592358 DOI: 10.1097/MPG.0b013e31803e171c] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 1.9] [Reference Citation Analysis]
473 Chaparro M. [Advances in the management of ulcerative colitis presented at Digestive Disease Week 2011]. Gastroenterol Hepatol 2011;34 Suppl 2:52-9. [PMID: 22330157 DOI: 10.1016/S0210-5705(11)70021-8] [Reference Citation Analysis]
474 Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794. [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055] [Cited by in Crossref: 1157] [Cited by in F6Publishing: 1053] [Article Influence: 105.2] [Reference Citation Analysis]
475 Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. 2007;13:1529-1535. [PMID: 17828784 DOI: 10.1002/ibd.20250] [Cited by in Crossref: 109] [Cited by in F6Publishing: 109] [Article Influence: 7.8] [Reference Citation Analysis]
476 Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis 2012;18:584-91. [PMID: 22009735 DOI: 10.1002/ibd.21847] [Cited by in Crossref: 78] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
477 Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14(16): 2544-2549 [PMID: 18442203 DOI: 10.3748/wjg.14.2544] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
478 Kim J, Kim HJ, Lee CK, Kim H, Shin AR, Kang KH, Kim MK, Park HJ, Chung HH, Hwang EJ. Predictors of Steroid Treatment Failure and Validation of Previous Models for Severe Attacks of Ulcerative Colitis. Intest Res 2012;10:251. [DOI: 10.5217/ir.2012.10.3.251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
479 Allez M. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases]. Gastroenterol Clin Biol 2008;32:467-77. [PMID: 18448294 DOI: 10.1016/j.gcb.2008.03.002] [Reference Citation Analysis]
480 Collins P, Rhodes J. Ulcerative colitis: diagnosis and management. BMJ. 2006;333:340-343. [PMID: 16902215 DOI: 10.1136/bmj.333.7563.340] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
481 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
482 Abelson JS, Michelassi F, Mao J, Sedrakyan A, Yeo H. Higher Surgical Morbidity for Ulcerative Colitis Patients in the Era of Biologics. Ann Surg 2018;268:311-7. [PMID: 28448381 DOI: 10.1097/SLA.0000000000002275] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 7.7] [Reference Citation Analysis]
483 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
484 Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
485 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
486 Komaki Y, Komaki F, Micic D, Yamada A, Suzuki Y, Sakuraba A. Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. J Gastroenterol Hepatol. 2017;32:1143-1151. [PMID: 27957761 DOI: 10.1111/jgh.13674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
487 Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8:571-581. [PMID: 24491514 DOI: 10.1016/j.crohns.2014.01.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
488 Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzén H, Tysk C, Järnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007;102:2513-9. [PMID: 17680849 DOI: 10.1111/j.1572-0241.2007.01435.x] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
489 Thorne K, Alrubaiy L, Akbari A, Samuel DG, Morrison-Rees S, Roberts SE. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review. Eur J Gastroenterol Hepatol 2016;28:369-82. [PMID: 26825217 DOI: 10.1097/MEG.0000000000000568] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
490 Irving PM. Recent advances in the management of inflammatory bowel disease. Clin Med (Lond) 2009;9:605-8. [PMID: 20095311 DOI: 10.7861/clinmedicine.9-6-605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
491 Ventham NT, Kalla R, Kennedy NA, Satsangi J, Arnott ID. Predicting outcomes in acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:405-415. [PMID: 25494666 DOI: 10.1586/17474124.2015.992880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
492 Zhao LZ, Wang SP, Li H. Treatment of ulcerative colitis with infliximab: an analysis of 2 cases. Shijie Huaren Xiaohua Zazhi 2011; 19(23): 2496-2500 [DOI: 10.11569/wcjd.v19.i23.2496] [Reference Citation Analysis]
493 Halloran B, Chang J, Shih DQ, McGovern D, Famulski K, Evaschesen C, Fedorak RN, Thiesen A, Targan S, Halloran PF. Molecular patterns in human ulcerative colitis and correlation with response to infliximab. Inflamm Bowel Dis 2014;20:2353-63. [PMID: 25397893 DOI: 10.1097/MIB.0000000000000239] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
494 Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Knox JF, Lemke K, Emmons J, Lundeen SH, Otterson MF, Binion DG. History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:176-181. [PMID: 18680197 DOI: 10.1002/ibd.20639] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
495 Huguet Malavés JM, Ruiz Sánchez L, Durá Ayet AB, Rodríguez García I, Latorre Sánchez M, Ferrer Arranz L, Tuset Ruiz JA, Tomé Toyosato A, Medina Chuliá E. [Effectiveness of maintenance azathioprine therapy without oral cyclosporine after severe attacks of ulcerative colitis refractory to endovenous steroids]. Gastroenterol Hepatol 2008;31:280-4. [PMID: 18448056 DOI: 10.1157/13119879] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
496 Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29:286-297. [PMID: 19132970 DOI: 10.1111/j.1365-2036.2008.03882.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 6.9] [Reference Citation Analysis]
497 Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum 2021;64:783-804. [PMID: 33853087 DOI: 10.1097/DCR.0000000000002037] [Reference Citation Analysis]
498 Reinisch W, Van Assche G, Befrits R, Connell W, D'haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg MS, Sorrentino D, van der Woude CJ, Vermeire S, Panes J. Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. Journal of Crohn's and Colitis 2012;6:248-58. [DOI: 10.1016/j.crohns.2011.11.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
499 Rizzello F, Praticò C, Calabrese C, Gionchetti P. Rescue therapy: ciclosporin or infliximab? Expert Review of Clinical Immunology 2014;9:503-5. [DOI: 10.1586/eci.13.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
500 Cheifetz AS, Rosenberg L. Infliximab decreases colectomy rates in moderate to severe ulcerative colitis: Big news or big deal? Inflammatory Bowel Diseases 2011;17:1626-8. [DOI: 10.1002/ibd.21498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
501 Herrlinger KR, Fellermann K, Stange EF. Tacrolimus--finally! Gut 2006;55:1224-5. [PMID: 16905691 DOI: 10.1136/gut.2006.093302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
502 da Luz Moreira A, Vogel JD, Baker M, Mor I, Zhang R, Fazio V. Does CT Influence the Decision to Perform Colectomy in Patients with Severe Ulcerative Colitis? J Gastrointest Surg 2009;13:504-7. [DOI: 10.1007/s11605-008-0732-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
503 Nakase H, Yoshino T, Matsuura M. Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use. Inflamm Bowel Dis 2014;20:2151-6. [PMID: 25029618 DOI: 10.1097/MIB.0000000000000130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
504 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
505 Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51:1202-1207; discussion 1202-1210. [PMID: 18536964 DOI: 10.1007/s10350-008-9364-7] [Cited by in Crossref: 204] [Cited by in F6Publishing: 160] [Article Influence: 14.6] [Reference Citation Analysis]
506 Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A review of infliximab use in ulcerative colitis. Clin Ther. 2008;30:223-230. [PMID: 18343261 DOI: 10.1016/j.clinthera.2008.02.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
507 Laharie D, Filippi J, Roblin X, Nancey S, Chevaux J, Hébuterne X, Flourié B, Capdepont M, Peyrin-biroulet L. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 2013;37:998-1004. [DOI: 10.1111/apt.12289] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
508 Choi CH, Kim Y, Kim YS, Ye BD, Lee KM, Lee BI, Jung S, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the Management of Ulcerative Colitis. Intest Res 2012;10:1. [DOI: 10.5217/ir.2012.10.1.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
509 Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65-72. [PMID: 29387331 DOI: 10.1177/2040622317742095] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
510 Bürger M, Schmidt C, Teich N, Stallmach A. Medical Therapy of Active Ulcerative Colitis. Viszeralmedizin 2015;31:236-45. [PMID: 26557831 DOI: 10.1159/000436959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
511 Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;CD007216. [PMID: 18646177 DOI: 10.1002/14651858.cd007216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
512 Olsen T, Goll R, Cui G, Husebekk A, Vonen B, Birketvedt GS, Florholmen J. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007;42:1312-1320. [PMID: 17852866 DOI: 10.1080/00365520701409035] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
513 Homma S, Kawamata F, Shibasaki S, Kawamura H, Takahashi N, Taketomi A. Does reduced-port laparoscopic surgery for medically uncontrolled ulcerative colitis do more harm than good? Asian J Endosc Surg. 2016;9:24-31. [PMID: 26490730 DOI: 10.1111/ases.12250] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
514 Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007;47:930-941. [PMID: 17567930 DOI: 10.1177/0091270007301623] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 5.6] [Reference Citation Analysis]
515 Ghosh S, Chaudhary R, Carpani M, Playford RJ. Is thiopurine therapy in ulcerative colitis as effective as in Crohn’s disease? Gut. 2006;55:6-8. [PMID: 16344570 DOI: 10.1136/gut.2005.074401] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
516 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
517 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
518 Meijer MJ, Mieremet-Ooms MA, van Duijn W, van der Zon AM, Hanemaaijer R, Verheijen JH, van Hogezand RA, Lamers CB, Verspaget HW. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:200-210. [PMID: 17206679 DOI: 10.1002/ibd.20051] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
519 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 657] [Cited by in F6Publishing: 574] [Article Influence: 65.7] [Reference Citation Analysis]
520 Kawalec P, Mikrut A, Łopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis: Biological therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1159-70. [DOI: 10.1111/jgh.12563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
521 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
522 Nelson R, Liao C, Fichera A, Rubin DT, Pekow J. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2014;20:14-20. [PMID: 24297054 DOI: 10.1097/01.MIB.0000437497.07181.05] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
523 Nos P, Hinojosa J. Ciclosporina en el brote grave de colitis ulcerosa. Gastroenterología y Hepatología 2005;28:629-31. [DOI: 10.1016/s0210-5705(05)71528-4] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
524 Büning J, Fellermann K. [Intensive care and inflammatory bowel diseases (IBD). The severe and fulminant flare]. Internist (Berl) 2011;52:833-40. [PMID: 21660632 DOI: 10.1007/s00108-010-2797-9] [Reference Citation Analysis]
525 Syal G, Robbins L, Kashani A, Bonthala N, Feldman E, Fleshner P, Vasiliauskas E, McGovern D, Ha C, Targan S, Melmed GY. Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis. Dig Dis Sci 2021;66:199-205. [PMID: 32170473 DOI: 10.1007/s10620-020-06177-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
526 Clemente V, Aratari A, Papi C, Vernia P. Short term colectomy rate and mortality for severe ulcerative colitis in the last 40 years. Has something changed? Dig Liver Dis 2016;48:371-5. [PMID: 26854257 DOI: 10.1016/j.dld.2015.12.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
527 Katz JA. Management of inflammatory bowel disease in adults. J Dig Dis 2007;8:65-71. [PMID: 17532817 DOI: 10.1111/j.1443-9573.2007.00287.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
528 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
529 Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol 2016;51:1062-8. [PMID: 27002981 DOI: 10.3109/00365521.2016.1149883] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
530 Vatn MH. Natural history and complications of IBD. Curr Gastroenterol Rep. 2009;11:481-487. [PMID: 19903424 DOI: 10.1007/s11894-009-0073-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
531 Han W, Xu J, Hu N, Mei Q, Liu M. Early predictors of responses and clinical outcomes of corticosteroid treatment for severe ulcerative colitis. Scandinavian Journal of Gastroenterology 2014;49:424-33. [DOI: 10.3109/00365521.2014.886716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
532 Mouzaoui S, Rahim I, Djerdjouri B. Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-α-induced oxidative stress, colitis and hepatotoxicity in mice. Int Immunopharmacol. 2012;12:302-311. [PMID: 22036766 DOI: 10.1016/j.intimp.2011.10.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
533 Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosintino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterol J 2021;9:507-16. [PMID: 33259773 DOI: 10.1177/2050640620977405] [Reference Citation Analysis]
534 Coward S, Heitman SJ, Clement F, Hubbard J, Proulx MC, Zimmer S, Panaccione R, Seow C, Leung Y, Datta I, Ghosh S, Myers RP, Swain M, Kaplan GG. Ulcerative colitis-associated hospitalization costs: a population-based study. Can J Gastroenterol Hepatol 2015;29:357-62. [PMID: 26079072 DOI: 10.1155/2015/627370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
535 Magnusson MK, Dahlén R, Strid H, Isaksson S, Simrén M, Lasson A, Bajor A, Ung KA, Ohman L. CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis. United European Gastroenterol J 2013;1:467-76. [PMID: 24917999 DOI: 10.1177/2050640613502962] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
536 Morisco F, Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S, Granata R, Orlando A, Marmo R, Riegler G. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis. 2011;43 Suppl 1:S40-S48. [PMID: 21195371 DOI: 10.1016/s1590-8658(10)60691-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
537 Prantera C. When is it time for surgery in severe ulcerative colitis?: . Inflammatory Bowel Diseases 2008;14:S240. [DOI: 10.1097/00054725-200810001-00112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
538 Akobeng AK. Infliximab for induction and maintenance theraphy for Ulcerative Colitis: . Journal of Pediatric Gastroenterology and Nutrition 2006;42:589-90. [DOI: 10.1097/01.mpg.0000221896.45910.9a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
539 Chao CY, Al Khoury A, Aruljothy A, Restellini S, Wyse J, Afif W, Bitton A, Lakatos PL, Bessissow T. High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival. Dig Dis Sci. 2019;64:518-523. [PMID: 30446928 DOI: 10.1007/s10620-018-5358-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
540 Patrick D, Doecke J, Irwin J, Hanigan K, Simms L, Howlett M, Radford-Smith G. The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis. Therap Adv Gastroenterol 2018;11:1756284818809789. [PMID: 30455743 DOI: 10.1177/1756284818809789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
541 Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panés J. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: A pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007; 13(15): 2193-2197 [PMID: 17465500 DOI: 10.3748/wjg.v13.i15.2193] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
542 Fichera A, Silvestri MT, Hurst RD, Rubin MA, Michelassi F. Laparoscopic restorative proctocolectomy with ileal pouch anal anastomosis: a comparative observational study on long-term functional results. J Gastrointest Surg. 2009;13:526-532. [PMID: 19015927 DOI: 10.1007/s11605-008-0755-9] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
543 Macdermott RP, Green JA, Ashley CC. What is the optimal therapy for severe ulcerative colitis?: . Inflammatory Bowel Diseases 2008;14:S228-31. [DOI: 10.1097/00054725-200810001-00107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
544 Candido FD, Fiorino G, Spadaccini M, Danese S, Spinelli A. Are Surgical Rates Decreasing in the Biological Era In IBD? Curr Drug Targets 2019;20:1356-62. [PMID: 31465283 DOI: 10.2174/1389450120666190426165325] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
545 Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7:77-90. [PMID: 30976420 DOI: 10.1093/gastro/goz004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
546 Lv R, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692. [PMID: 24475168 DOI: 10.1371/journal.pone.0086692] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
547 Takeuchi K, Shimoyama T, Yamamoto T. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis. Dig Dis 2018;36:106-12. [PMID: 29050007 DOI: 10.1159/000481815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
548 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 381] [Article Influence: 138.3] [Reference Citation Analysis]
549 Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol 2018;11:1756283X17745029. [PMID: 29383027 DOI: 10.1177/1756283X17745029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
550 Fidder HH, Heijmans R, Chowers Y, Bar-Meir S, Avidan B, Pena AS, Crusius JB. TNF-857 polymorphism in Israeli Jewish patients with inflammatory bowel disease. Int J Immunogenet. 2006;33:81-85. [PMID: 16611251 DOI: 10.1111/j.1744-313x.2006.00572.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
551 Holme O, Thiis-Evensen E, Vatn MH. Treatment of fulminant ulcerative colitis with cyclosporine A. Scand J Gastroenterol 2009;44:1310-4. [PMID: 19891581 DOI: 10.3109/00365520903222673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
552 Lakatos PL, Lakatos L. Ulcerative proctitis: a review of pharmacotherapy and management. Expert Opin Pharmacother. 2008;9:741-749. [PMID: 18345952 DOI: 10.1517/14656566.9.5.741] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
553 Molnár T, Farkas K, Szepes Z, Nagy F, Wittmann T. Long-term outcome of infliximab therapy is highly comparable in a Danish and in a Hungarian tertiary center. Scandinavian Journal of Gastroenterology 2011;46:248-9. [DOI: 10.3109/00365521.2010.522725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
554 Andersson D, Kotarsky K, Wu J, Agace W, Duan RD. Expression of alkaline sphingomyelinase in yeast cells and anti-inflammatory effects of the expressed enzyme in a rat colitis model. Dig Dis Sci. 2009;54:1440-1448. [PMID: 18989780 DOI: 10.1007/s10620-008-0509-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
555 Barreiro-de Acosta M, Lorenzo A, Mera J, Dominguez-Muñoz JE. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009;3:271-6. [PMID: 21172286 DOI: 10.1016/j.crohns.2009.06.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
556 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011;86:748-757. [PMID: 21803957 DOI: 10.4065/mcp.2011.0074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
557 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 162] [Article Influence: 10.5] [Reference Citation Analysis]
558 Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, Kopylov U, Tsianos E, Mantzaris GJ, Ben-Horin S. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014;46:135-139. [PMID: 24246151 DOI: 10.1016/j.dld.2013.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
559 Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci 2016;12:1097-109. [PMID: 27695502 DOI: 10.5114/aoms.2016.58682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
560 Ginard D, Khorrami S, Pérez-Carazo L, Tavío-Hernández E, López-Sanromán A, García-Alvarado M, Muñoz F, Ibáñez-Samaniego L, Marín-Jiménez I, Guevara J, Casellas F. [Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study]. Gastroenterol Hepatol 2016;39:369-76. [PMID: 27005800 DOI: 10.1016/j.gastrohep.2016.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
561 Rizzello F, Campieri M, Tambasco R, Straforini G, Brugnera R, Poggioli G, Gionchetti P. Medical treatment and management of severe ulcerative colitis. Dig Liver Dis 2008;40 Suppl 2:S280-4. [PMID: 18599001 DOI: 10.1016/S1590-8658(08)60538-1] [Reference Citation Analysis]
562 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
563 Alexakis C, Pollok RCG. Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. World J Gastrointest Surg 2015; 7(12): 360-369 [PMID: 26730281 DOI: 10.4240/wjgs.v7.i12.360] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
564 Monterubbianesi R, Aratari A, Armuzzi A, Daperno M, Biancone L, Cappello M, Annese V, Riegler G, Orlando A, Viscido A. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis. 2014;8:852-858. [PMID: 24472490 DOI: 10.1016/j.crohns.2014.01.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
565 Øresland T, Bemelman WA, Sampietro GM, Spinelli A, Windsor A, Ferrante M, Marteau P, Zmora O, Kotze PG, Espin-basany E, Tiret E, Sica G, Panis Y, Faerden AE, Biancone L, Angriman I, Serclova Z, de Buck van Overstraeten A, Gionchetti P, Stassen L, Warusavitarne J, Adamina M, Dignass A, Eliakim R, Magro F, D’hoore A. European evidence based consensus on surgery for ulcerative colitis. Journal of Crohn's and Colitis 2015;9:4-25. [DOI: 10.1016/j.crohns.2014.08.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 137] [Article Influence: 23.3] [Reference Citation Analysis]
566 Salameh R, Kirchgesner J, Allez M, Carbonnel F, Meyer A, Gornet JM, Beaugerie L, Amiot A. Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Aliment Pharmacol Ther 2020;51:1096-104. [PMID: 32342994 DOI: 10.1111/apt.15751] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
567 Travis S. Review article: saving the colon in severe colitis - the case for medical therapy. Aliment Pharmacol Ther 2006;24 Suppl 3:68-73. [PMID: 16961749 DOI: 10.1111/j.1365-2036.2006.03064.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
568 Blair SA, Kane SV, Clayburgh DR, Turner JR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest 2006;86:191-201. [DOI: 10.1038/labinvest.3700373] [Cited by in Crossref: 182] [Cited by in F6Publishing: 178] [Article Influence: 11.4] [Reference Citation Analysis]
569 Vanhove W, Nys K, Vermeire S. Therapeutic innovations in inflammatory bowel diseases. Clin Pharmacol Ther. 2016;99:49-58. [PMID: 26509246 DOI: 10.1002/cpt.286] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
570 Narula N, Fine M, Colombel J, Marshall JK, Reinisch W. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis. Inflammatory Bowel Diseases 2015;21:1683-94. [DOI: 10.1097/mib.0000000000000350] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 6.1] [Reference Citation Analysis]
571 Kountouras J, Zavos C, Chatzopoulos D. Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis. Gastroenterology 2005;129:1138-9. [DOI: 10.1053/j.gastro.2005.07.047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
572 Järnerot G. How to judge the response to treatment in ulcerative colitis?: . Inflammatory Bowel Diseases 2008;14:S222-3. [DOI: 10.1002/ibd.20546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
573 Borren NZ, Khalili H, Luther J, Colizzo FP, Garber JJ, Ananthakrishnan AN. Second-Look Endoscopy in Hospitalized Severe Ulcerative Colitis: A Retrospective Cohort Study. Inflamm Bowel Dis 2019;25:750-5. [PMID: 30204864 DOI: 10.1093/ibd/izy282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
574 Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol 2011; 17(27): 3204-3212 [PMID: 21912469 DOI: 10.3748/wjg.v17.i27.3204] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
575 Gustavsson A, Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Verbaan H. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther. 2010;32:984-989. [PMID: 20937043 DOI: 10.1111/j.1365-2036.2010.04435.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 113] [Article Influence: 10.6] [Reference Citation Analysis]
576 Stokkers PC, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:201-10. [PMID: 16901384 DOI: 10.1007/s11938-006-0039-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
577 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
578 Malayandi R, Kondamudi PK, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv and Transl Res 2014;4:187-202. [DOI: 10.1007/s13346-013-0185-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
579 Samaan MA, Bagi P, Vande Casteele N, D’haens GR, Levesque BG. An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterology Clinics of North America 2014;43:479-94. [DOI: 10.1016/j.gtc.2014.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
580 Song F, Zhang Y, Pan Z, Hu X, Zhang Q, Huang F, Ye X, Huang P. The role of alcohol dehydrogenase 1C in regulating inflammatory responses in ulcerative colitis. Biochem Pharmacol 2021;192:114691. [PMID: 34293286 DOI: 10.1016/j.bcp.2021.114691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
581 Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326. [PMID: 27220829 DOI: 10.3310/hta20390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
582 Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepatol. 2011;26:1114-1122. [PMID: 21299620 DOI: 10.1111/j.1440-1746.2011.06688.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
583 Huang ML, Ran ZH, Shen J, Li XB, Xu XT, Xiao SD. Efficacy and safety of adalimumab in Crohn's disease: Meta-analysis of placebo-controlled trials: Adalimumab in Crohn's disease. Journal of Digestive Diseases 2011;12:165-72. [DOI: 10.1111/j.1751-2980.2011.00493.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
584 Szepes Z, Molnár T, Farkas K, Horváth G, Nagy F, Nyári T, Wittmann T. Better quality of life after surgery treatment in patients with colitis ulcerosa: what is the price? Orvosi Hetilap 2010;151:1264-9. [DOI: 10.1556/oh.2010.28908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
585 Johansson M, Norrgard O, Forsgren S. Are Neurotrophins Important in Ulcerative Colitis? Annals of the New York Academy of Sciences 2007;1107:290-9. [DOI: 10.1196/annals.1381.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
586 Burger D, Travis S. Conventional Medical Management of Inflammatory Bowel Disease. Gastroenterology 2011;140:1827-1837.e2. [DOI: 10.1053/j.gastro.2011.02.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 120] [Article Influence: 12.3] [Reference Citation Analysis]
587 Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update: . European Journal of Gastroenterology & Hepatology 2010;22:779-86. [DOI: 10.1097/meg.0b013e328331b654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
588 Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005;22:907-16. [PMID: 16268964 DOI: 10.1111/j.1365-2036.2005.02680.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
589 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
590 García-Bosch O, Aceituno M, Ordás I, Etchevers J, Sans M, Feu F, Panés J, Ricart E. Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study. Dig Dis Sci 2016;61:2051-9. [PMID: 26921082 DOI: 10.1007/s10620-016-4089-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
591 D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786. [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038] [Cited by in Crossref: 629] [Cited by in F6Publishing: 562] [Article Influence: 39.3] [Reference Citation Analysis]
592 Chun J, Lee C, Kwon JE, Hwang SW, Kim SG, Kim JS, Jung HC, Im JP. Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis. Intest Res. 2015;13:50-59. [PMID: 25691843 DOI: 10.5217/ir.2015.13.1.50] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
593 Carbonnel F. Prise en charge d’une rectocolite hémorragique sévère ou corticorésistante. Gastroentérologie Clinique et Biologique 2007;31:398-403. [DOI: 10.1016/s0399-8320(07)89399-7] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
594 Chinen T, Kobayashi T, Ogata H, Takaesu G, Takaki H, Hashimoto M, Yagita H, Nawata H, Yoshimura A. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNgamma and IL-4 are involved. Gastroenterology. 2006;130:373-388. [PMID: 16472593 DOI: 10.1053/j.gastro.2005.10.051] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 3.7] [Reference Citation Analysis]
595 Böcker U. Infliximab in ulcerative colitis. Scandinavian Journal of Gastroenterology 2009;41:997-1000. [DOI: 10.1080/00365520600857490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
596 Tremelling M, Waller S, Bredin F, Greenfield S, Parkes M. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. Inflamm Bowel Dis. 2006;12:178-184. [PMID: 16534418 DOI: 10.1097/01.MIB.0000217766.90766.37] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
597 Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs 2009;14:505-21. [PMID: 19656075 DOI: 10.1517/14728210903146882] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
598 Ng SC, Kamm MA. Fulminant Crohnʼs colitis: When only an antibody will do: . Inflammatory Bowel Diseases 2007;13:971-4. [DOI: 10.1002/ibd.20139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
599 Matson J, Ramamoorthy S, Lopez NE. The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review. J Clin Med 2021;10:3362. [PMID: 34362144 DOI: 10.3390/jcm10153362] [Reference Citation Analysis]
600 Prantera C. When is it time for surgery in severe ulcerative colitis? Inflamm Bowel Dis 2008;14 Suppl 2:S240. [PMID: 18816781 DOI: 10.1002/ibd.20694] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
601 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
602 Fanjiang G, Russell GH, Katz AJ. Short- and Long-term Response to and Weaning from Infliximab Therapy in Pediatric Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 2007;44:312-7. [DOI: 10.1097/mpg.0b013e31802e98d4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
603 Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1169-86. [PMID: 30605549 DOI: 10.1093/ibd/izy383] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
604 Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081-1088. [PMID: 19577010 DOI: 10.1016/j.cgh.2009.06.024] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 8.4] [Reference Citation Analysis]
605 Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103-110. [PMID: 17142106 DOI: 10.1016/j.cgh.2006.09.033] [Cited by in Crossref: 363] [Cited by in F6Publishing: 303] [Article Influence: 22.7] [Reference Citation Analysis]
606 Buhr H, Kroesen A. Therapierefraktäre chronisch entzündliche Darmerkrankungen: Eine chirurgische Herausforderung. Chirurg 2013;84:945-50. [DOI: 10.1007/s00104-013-2516-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
607 Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598-1619. [PMID: 20198712 DOI: 10.1002/ibd.21219] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 11.1] [Reference Citation Analysis]
608 Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther. 2007;25:1055-1060. [PMID: 17439506 DOI: 10.1111/j.1365-2036.2007.03300.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 5.7] [Reference Citation Analysis]
609 Shah SC, Naymagon S, Panchal HJ, Sands BE, Cohen BL, Dubinsky MC. Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. Inflamm Bowel Dis 2018;24:651-9. [PMID: 29462380 DOI: 10.1093/ibd/izx039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
610 Fiorino G, Peyrin-Biroulet L, Repici A, Malesci A, Danese S. Adalimumab in ulcerative colitis: hypes and hopes. Expert Opin Biol Ther 2011;11:109-16. [PMID: 21133817 DOI: 10.1517/14712598.2011.541435] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
611 Wang L, Bai AP. Biological therapies for inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2010; 18(2): 107-112 [DOI: 10.11569/wcjd.v18.i2.107] [Reference Citation Analysis]
612 Travis SP. New thinking: theory vs practice. A case study illustrating evidence-based therapeutic decision making. Colorectal Dis 2006;8 Suppl 1:25-9. [PMID: 16594961 DOI: 10.1111/j.1463-1318.2006.00989.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
613 Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol. 2007;23:395-399. [PMID: 17545775 DOI: 10.1097/mog.0b013e32815b601b] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
614 Branche J, Cortot A, Bourreille A, Coffin B, de Vos M, de Saussure P, Seksik P, Marteau P, Lemann M, Colombel JF. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis. 2009;15:1044-1048. [PMID: 19137604 DOI: 10.1002/ibd.20858] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
615 Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453-468. [PMID: 20370724 DOI: 10.1111/j.1440-1746.2010.06241.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 8.1] [Reference Citation Analysis]
616 Gupta A, Street AC, Macrae FA. Tumour necrosis factor α inhibitors: screening for tuberculosis infection in inflammatory bowel disease. Medical Journal of Australia 2008;188:168-70. [DOI: 10.5694/j.1326-5377.2008.tb01565.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
617 Rodríguez-Moranta F, Soriano-Izquierdo A, Guardiola J. [Current status of treatment of inflammatory bowel disease]. Cir Esp 2007;82:254-9. [PMID: 18021623 DOI: 10.1016/s0009-739x(07)71722-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
618 Zeitz J, Huber M, Rogler G. [Serious course of a miliary tuberculosis in a 34-year-old patient with ulcerative colitis and HIV infection under concomitant therapy with infliximab]. Med Klin (Munich) 2010;105:314-8. [PMID: 20455057 DOI: 10.1007/s00063-010-1046-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
619 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
620 Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg 2007;16:164-71. [PMID: 17602971 DOI: 10.1053/j.sempedsurg.2007.04.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
621 Kohn A, Fano V, Monterubbianesi R, Davoli M, Marrollo M, Stasi E, Perucci C, Prantera C. Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: a 10-year cohort study. Dig Liver Dis. 2012;44:369-374. [PMID: 22197692 DOI: 10.1016/j.dld.2011.11.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
622 Corte C, Saxena P, Tattersall S, Selinger C, Leong RW. When to use biological agents in inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:1141-9. [PMID: 22188169 DOI: 10.1111/j.1440-1746.2011.07056.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
623 Yamamoto T, Carvello M, Lightner AL, Spinelli A, Kotze PG. Up-to-date surgery for ulcerative colitis in the era of biologics. Expert Opin Biol Ther. 2020;20:391-398. [PMID: 31948294 DOI: 10.1080/14712598.2020.1718098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
624 Halpin SJ, Hamlin PJ, Ford AC. Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2010;32:1294-5. [DOI: 10.1111/j.1365-2036.2010.04478.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
625 Park SH, Yang SK, Hong SM, Park SK, Kim JW, Lee HJ, Yang DH, Jung KW, Kim KJ, Ye BD. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig Dis Sci. 2013;58:3592-3599. [PMID: 23979435 DOI: 10.1007/s10620-013-2828-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
626 Narula N, Jharap B, Colombel J. Management of Severe Ulcerative Colitis. Curr Treat Options Gastro 2015;13:59-76. [DOI: 10.1007/s11938-014-0036-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
627 Grossman AB, Baldassano RN. Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2008;2:105-124. [PMID: 19072374 DOI: 10.1586/17474124.2.1.105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
628 Schmidt KJ, Müller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, Herrlinger KR, Fellermann K, Büning J. Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. J Crohns Colitis 2016;10:31-7. [PMID: 26419459 DOI: 10.1093/ecco-jcc/jjv175] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
629 Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1057-1064. [PMID: 23581515 DOI: 10.1111/apt.12313] [Cited by in Crossref: 108] [Cited by in F6Publishing: 87] [Article Influence: 12.0] [Reference Citation Analysis]
630 Farkas K, Molnár T, Szepes Z. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;8:695-702. [DOI: 10.1586/17474124.2014.909726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
631 Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55:1575-1580. [PMID: 16772310 DOI: 10.1136/gut.2005.090316] [Cited by in Crossref: 239] [Cited by in F6Publishing: 191] [Article Influence: 14.9] [Reference Citation Analysis]
632 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
633 Law JK, Salh B, Yoshida EM. All that bleeds is not infliximab-refractory ulcerative colitis. Can J Gastroenterol 2009;23:91-2. [PMID: 19214282 DOI: 10.1155/2009/983121] [Reference Citation Analysis]
634 Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006;40:476-81. [PMID: 16825928 DOI: 10.1097/00004836-200607000-00004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
635 Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ. 2010;11:67-76. [PMID: 19844750 DOI: 10.1007/s10198-009-0199-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
636 Leblanc S, Allez M, Seksik P, Flourié B, Peeters H, Dupas JL, Bouguen G, Peyrin-Biroulet L, Duclos B, Bourreille A. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2011;106:771-777. [PMID: 21386832 DOI: 10.1038/ajg.2011.62] [Cited by in Crossref: 68] [Cited by in F6Publishing: 50] [Article Influence: 6.2] [Reference Citation Analysis]
637 Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol 2006;22:370-6. [PMID: 16760752 DOI: 10.1097/01.mog.0000231810.87901.e8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
638 Bossa F, Fiorella S, Caruso N, Accadia L, Napolitano G, Valvano MR, Andriulli A, Annese V. Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. Am J Gastroenterol 2007;102:601-8. [DOI: 10.1111/j.1572-0241.2006.01007.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
639 Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:395-405. [DOI: 10.1586/egh.09.24] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
640 Ollech JE, Normatov I, Peleg N, Dalal SR, Pekow J, Micic D, Cohen RD, Rubin DT, Sakuraba A. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis 2020;35:2113-6. [PMID: 32710391 DOI: 10.1007/s00384-020-03703-x] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
641 Zwiers A, Bouma G. Recent advances in the etiology and treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2006;2:245-56. [PMID: 20477075 DOI: 10.1586/1744666X.2.2.245] [Reference Citation Analysis]
642 Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013;37:129-136. [PMID: 23121200 DOI: 10.1111/apt.12118] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
643 Kang MX, Jia H. Progress in mechanisms of visceral hypersensitivity in irritable bowel syndrome. Shijie Huaren Xiaohua Zazhi 2008; 16(14): 1554-1558 [DOI: 10.11569/wcjd.v16.i14.1554] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
644 Lavi I, Levinson D, Peri I, Nimri L, Hadar Y, Schwartz B. Orally administered glucans from the edible mushroom Pleurotus pulmonarius reduce acute inflammation in dextran sulfate sodium-induced experimental colitis. Br J Nutr. 2010;103:393-402. [PMID: 19772681 DOI: 10.1017/s0007114509991760] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
645 Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, Ben Yehoyada M, Mould DR. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20:2247-2259. [PMID: 25358062 DOI: 10.1097/mib.0000000000000212] [Cited by in Crossref: 170] [Cited by in F6Publishing: 63] [Article Influence: 24.3] [Reference Citation Analysis]
646 Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Translational Research 2014;163:533-56. [DOI: 10.1016/j.trsl.2014.01.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
647 Huang BB, Han LC, Liu GF, Lv XD, Gu GL, Li SQ, Chen L, Wang HQ, Zhan LL, Lv XP. Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report. World J Gastroenterol 2020; 26(46): 7425-7435 [PMID: 33362394 DOI: 10.3748/wjg.v26.i46.7425] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
648 Pandey S, Luther G, Umanskiy K, Malhotra G, Rubin MA, Hurst RD, Fichera A. Minimally invasive pouch surgery for ulcerative colitis: is there a benefit in staging? Dis Colon Rectum. 2011;54:306-310. [PMID: 21304301 DOI: 10.1007/dcr.0b013e31820347b4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
649 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 730] [Article Influence: 68.8] [Reference Citation Analysis]
650 de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:985-1002. [PMID: 21936033 DOI: 10.1002/ibd.21871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
651 Naves JE, Llaó J, Ruiz-cerulla A, Romero C, Mañosa M, Lobatón T, Cabré E, Garcia-planella E, Guardiola J, Domènech E. Long-term Comparative Efficacy of Cyclosporine- or Infliximab-based Strategies for the Management of Steroid-refractory Ulcerative Colitis Attacks: . Inflammatory Bowel Diseases 2014;20:1375-81. [DOI: 10.1097/mib.0000000000000101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
652 Feagan B. Infliximab, Adalimumab and Certolizumab: Beneficial and Adverse Effects (Past). Inflammatory Bowel Diseases 2006;12:S6. [DOI: 10.1097/00054725-200610003-00013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
653 Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, Rafferty J. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2014;57:5-22. [PMID: 24316941 DOI: 10.1097/dcr.0000000000000030] [Cited by in Crossref: 107] [Cited by in F6Publishing: 27] [Article Influence: 13.4] [Reference Citation Analysis]
654 Jiang XL, Cui HF, Gao J, Fan H. Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis. J Clin Gastroenterol 2015;49:582-8. [PMID: 25844841 DOI: 10.1097/MCG.0000000000000319] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
655 Windsor A, Michetti P, Bemelman W, Ghosh S. The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy. Inflamm Bowel Dis. 2013;19:2695-2703. [PMID: 23846487 DOI: 10.1097/mib.0b013e318292fae6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
656 Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D, Ippoliti A, Shih D, Targan S, Fleshner P. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg. 2015;261:487-496. [PMID: 24950263 DOI: 10.1097/sla.0000000000000757] [Cited by in Crossref: 107] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
657 Shah SC, Colombel J, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2016;14:1245-1255.e8. [DOI: 10.1016/j.cgh.2016.01.015] [Cited by in Crossref: 132] [Cited by in F6Publishing: 122] [Article Influence: 22.0] [Reference Citation Analysis]
658 Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World J Gastroenterol 2013; 19(7): 1091-1097 [PMID: 23467174 DOI: 10.3748/wjg.v19.i7.1091] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
659 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
660 Sands BE. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am. 2006;86:1045-1064. [PMID: 16905423 DOI: 10.1016/j.suc.2006.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
661 Wong U, Cross RK. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol 2017;13:1039-46. [PMID: 28876147 DOI: 10.1080/17425255.2017.1377180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
662 Bressler B, Law JK, Al Nahdi Sheraisher N, Atkinson K, Byrne MF, Chung HV, Fishman M, Partovi N, Pearson D, Penner R, Enns RA. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol 2008;22:937-40. [PMID: 19018340 DOI: 10.1155/2008/749547] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
663 Pellino G, Keller DS, Sampietro GM, Carvello M, Celentano V, Coco C, Colombo F, Geccherle A, Luglio G, Rottoli M, Scarpa M, Sciaudone G, Sica G, Sofo L, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. Tech Coloproctol 2020;24:397-419. [PMID: 32124113 DOI: 10.1007/s10151-020-02175-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
664 Cury DB, Cury MS, Elias GVH, Mizsputen SJ. Infliximab to treat severe ulcerative colitis. World J Gastroenterol 2009; 15(14): 1771-1773 [PMID: 19360923 DOI: 10.3748/wjg.15.1771] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
665 Tissot B, Visée S, Pilette C, Prophette B, Puechal X. Lymphocytic meningitis with infliximab for ulcerative colitis. Gastroentérologie Clinique et Biologique 2006;30:1420-2. [DOI: 10.1016/s0399-8320(06)73577-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
666 Nilsson Å. Optimizing management of distal ulcerative colitis. Scandinavian Journal of Gastroenterology 2009;41:511-23. [DOI: 10.1080/00365520600575738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
667 Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. J Crohns Colitis 2021;15:733-41. [PMID: 33175102 DOI: 10.1093/ecco-jcc/jjaa226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
668 Kedia S, Ahuja V, Makharia GK. Golimumab for moderately to severely active ulcerative colitis. Expert Rev Clin Pharmacol 2016;9:1273-82. [PMID: 27498886 DOI: 10.1080/17512433.2016.1221759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
669 Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [Reference Citation Analysis]
670 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
671 Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis. 2013;19:1490-1498. [PMID: 23615528 DOI: 10.1097/mib.0b013e318281f362] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 2.9] [Reference Citation Analysis]